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Recent research developments have found that the long recognized 
hyperadrenergic state of opiate withdrawal may be mediated by hyperactivity 
of the locus coeruleus- a nucleus in the anterior pons which is almost entirely 
composed of norepinephrine. This suggested that clonidine and a 2 adrenergic 
agonist might be effective in inhibiting LC firing and be clinically applicable in 
attenuating withdrawal symptoms. The current study extends this idea by using 
an opiate antagonist (naloxone or naltrexone) to precipitate a possibly more 
intense but shorter lived abstinence syndrome while attempting to minimize 
withdrawal symptoms with clonidine. 
Five men and three women with methadone maintenance doses of 10-35 
mg on admission were detoxified on a combination of either clonidine and 
naloxone or clonidine and naltrexone after abrupt termination of methadone. 
The clonidine/antagonist protocol proved to be a safe effective method of 
detoxification without evidence of cardiovascular compromise or uncontrollable 
severe abstinence symptoms. Most of the withdrawal syndrome was completed 
within three days of methadone termination while a few mild symptoms 
persisted for up to one week. A single 50 mg maintenance dose of naltrexone 
could be administered on the fifth day. Although initial clonidine requirements 
exceeded those needed in previous studies utilizing clonidine alone, the subjects 
were able to achieve lower doses and finish the clonidine taper sooner. The 
most prominent symptoms during detoxification included anxiety, bone and 
muscle aching, anorexia, insomnia, restlessness, and hot and cold flashes. 
Suggestions are made for possible application of this method to appropriate 
methadone maintenance clients. 
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The use of opiate compounds dates back to at least the third century 
B.C. wnen opium was used in many medicinal compounds. Opium eating 
and smoking became popular in Europe and the Orient and by the 18th 
century it was apparent that opium use could be associated with dependence. 
At that time, however, it was believed that the lower classes were most 
susceptible to its effects and that the upper class showed "no noticeable 
behavioral changes." 123,p.70 Opium continued to be deemed useful for 
virtually all ailments and it wasn't until the 19th century that the medical 
community raised serious questions about the addictive potential of opium for 
all classes. 
By 1868, both oral and intravenous morphine had come into use in the 
belief that it was safer and preferable to opium in the treatment of disease. 
During the late 1870's, large amounts of the drug were being imported into 
the United States. When the addictive potential of morphine became obvious, 
the general public fear of opiate addiction led to the passage of many 
antimorphine laws in the 1890's as well as a prohibition on the importation of 
123 
smoking opium in 1909. 
By 1900, there were an estimated 250,000 opiate addicts in the United 
123 
States. It should be emphasized that physicians were not solely 
responsible for the opiate problem. Many individuals had become addicted 
through the use of narcotic containing patent medicines. The first serious 
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action taken by the federal government to deal with this problem came in 
1915 with the passage of the Harrison Narcotic Act. Attempts were made to 
regulate opiate supplies by registering physicians and pharmacists; placing a 
limit on the amount of opiate compounds present in patent medicines; and 
prohibiting addiction maintenance to all individuals unless they had 
untreatable pain, had become addicted during previous medical care or were 
123 124 
elderly debilitated individuals with a long addiction history. ’ 
Heroin addiction did not become a problem until the late 1910's. 
Contrary to popular belief, this drug was not introduced as a harmless cure 
for morphine addiction. Rather, it was initially used as a cough suppressant. 
It became widely abused by opiate addicts only after restrictive laws were 
enforced and addicts found it necessary to turn to other sources to support 
97 
their habits. 
The search for a safe effective method of opiate detoxification has 
been ongoing since the 1800's. Detoxification is defined as "... the process 
whereby an individual who is physically dependent on the drug ... is taken off 
87 
that drug ..." This does not imply a cure since the prevention of relapse is 
not necessarily a goal. Most recently, specific emphasis has been placed on a 
nonaddicting method of opiate detoxification for the estimated 80,000 
individuals on methadone maintenance - 10,000 of whom are attempting 
88 
withdrawal at any time. These individuals have been knowingly placed on 
an addictive drug which will prevent the onset of abstinence in an attempt to 
eliminate the need to seek out an illegal substance (i.e. heroin) while they 
work on the problems underlying opiate abuse. 
Recent clinical trials with the a 2 adrenergic agonist clonidine have 
been promising. However, the protocol requires up to two weeks of clonidine 
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therapy and does not eliminate the need for a 5-10 day period after 
methadone is stopped before antagonist aftercare therapy can be begun. The 
purpose of this study is to evaluate the effectiveness and safety of a 
clonidine/antagonist combination in methadone detoxification paying specific 
attention to its ability to shorten both the length of the withdrawal period 
and the lag time before induction onto maintenance doses of the opiate 
antagonist naltrexone. 
DEFINITIONS 
DRUG ADDICTION - As recounted by Isbell, ^ the World Health 
Organization defined drug addiction as "... a state of periodic or chronic 
intoxication detrimental to the individual and to society, produced by the 
repeated consumption of a drug (natural or synthetic). Its characteristics 
include 1) an overpowering desire or need (compulsion) to continue taking the 
drug and to obtain it by any means. 2) a tendency to increase the dose. 3) a 
psychic (psychological) and sometimes a physical dependence on the effects of 
the drug." 
76 
Isbell defined more specific aspects of opiate addiction: 
TOLERANCE - "...a decreasing effect on repetition of the same dose of a 
drug." 
PHYSICAL DEPENDENCE _ "... the development of an altered 
physiologic state which requires continued administration of a drug to prevent 
the appearance of a characteristic illness termed an "abstinence syndrome." 
EMOTIONAL DEPENDENCE - "... a substitution of the use of the drug for 
other types of adaptive behavior." 
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OPIATE DEPENDENCE AND WITHDRAWAL SYNDROMES 
The opiate dependence and withdrawal syndromes have been studied and 
63 
well documented over the past century. Himmelsbach described the 
morphine addiction syndrome in detail noting that the morphine addict 
exhibited evidence of increased appetite, body temperature and ESR; disturbed 
sleep patterns; lowered respiratory rate, blood pressure, HCT and serum lactic 
acid levels; as well as normal blood sugar and basal metabolic rate. 
Isbell^ studied the morphine withdrawal syndrome and observed the onset 
within 12 - 14 hours of abstinence of occasional yawning, mild perspiration, 
rhinorrhea, and lacrimation. Gooseflesh, muscle twitching, muscle aches, cold 
flashes and mydriasis were evident at 18-24 hours. Thirty-six hours marked the 
onset of restlessness, vomiting, diarrhea, anorexia, weight loss and changes in 
vital signs - i.e. respiratory rate, blood pressure, temperature. These symptoms 
persisted until 72 hours and subsequently declined in intensity with a return 
toward baseline in 7 - 10 days. Isbell did note however that individuals 
complained about insomnia, weakness, nervousness and muscle pain for weeks 
thereafter. 
91 
Kolb made a more detailed study of the morphine abstinence syndrome 
during the first ten days of withdrawal noting that acute withdrawal was 
characterized by insomnia; decreased caloric intake and body weight; and 
elevated blood sugar levels, rectal temperature, respiratory rate, blood 
pressure, and basal metabolic rate. He found that blood sugar levels returned 
to pre-withdrawal levels within four days and that caloric intake recovered 




the ten day study leading him to conclude that withdrawal was not complete in 
10 days. 
63 
Hirnmelsbach also believed that the abstinence syndrome lasted longer 
than 10 days and conducted a longitudinal study in which he observed drug 
addicts during three time periods - addiction; the first 15 days of withdrawal; 
and approximately once a month for up to nine months after withdrawal. He 
found that recovery or the achievement of steady state levels of blood sugar, 
lactic acid and inorganic phosphate occurred within the first month post¬ 
withdrawal while phosphate remained subnormal at nine months. Two to tnree 
months were necessary to achieve recovery of body temperature, caloric 
intake, sleep patterns, and respiratory rate. The discrepancy between Kolb and 
Hirnmelsbach with regard to caloric intake can be explained by the length of 
the observation period. The initial recovery of appetite at one week is followed 
by a two month period of increased caloric intake over addiction levels. Blood 
pressure, body weight, basal metabolic rate, hematocrit and erythrocyte 
sedimentation rate did not stablize for four to six months. As with inorganic 
phosphate, the basal metabolic rate was felt to be subnormal at nine months. 
Martin ^ described this prolonged recovery period in rats and broke it 
down into primary and secondary or protracted abstinence syndromes. The 
primary abstinence syndrome began 8-16 hours after abstinence and lasted for 
72 hours. It was characterized by weight loss decrease in body temperature, 
hostile behavior, and wet dog shakes. The protracted abstinence syndrome 
which included increases in body weight, temperature, BMR, and water 
consumption lasted up to six months. Martin later went on to study the 
same phenomenon in humans. The primary abstinence syndrome of elevated 
blood pressure, temperature, respiratory rate, heart rate, mydriasis, and 
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increased sensitivity of the respiratory center to CC^ lasted for approximately 
two months while the protracted abstinence period characterized by diminished 
blood pressure, heart rate, and temperature; decreased sensitivity of the 
respiratory center to CC^; and miosis became apparent within six to nine weeks 
after morphine withdrawal and lasted up to 30 weeks. Martin also noted that 
elevated levels of urine epinephrine could be detected for 17 weeks post 
withdrawal. 
The heroin and methadone abstinence syndromes are slightly different 
from that of morphine. Heroin is a shorter acting compound with an earlier 
onset of withdrawal symptoms at 8-12 hours, a shorter peak at 48-72 hours and 
a faster recovery period of 5-10 days. Methadone has a longer period of action 
than morphine with a slower onset of withdrawal at 36-72 hours, a later peak at 
72-96 hours and a longer recovery period of 14-21 days. Although the 
methadone withdrawal symptoms are less intense tnan those of morphine or 
heroin, weakness, fatigue, aching and insomnia can still be apparent up to six 
76 87 
weeks post-withdrawal. ’ 
Opiate withdrawal symptoms have been graded in an attempt to judge 
87 
clinical severity. This system is as follows: 
Grade 0: Drug craving, anxiety, drug seeking behavior 
Grade 1: Yawning, perspiration, lacrimation, rhinorrhea yen sleep 
Grade 2: Mydriasis, gooseflesh, muscle twitches, hot and cold flashes, 
chills, aching bones and muscles, anorexia, irritability 
Grade 3: Insomnia, fever, increased respiratory rate and blood pressure, 
restlessness, abdominal cramps, nausea, vomiting, diarrhea, weakness, 
weight loss. 
It is important to realize that this chart is an approximation. Not all 
patients will experience the entire spectrum of symptoms, nor will they occur 
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in this exact order. Patients tend to exhibit a particular set of symptoms which 
repeat themselves each time that they withdraw. 
DETOXIFICATION TECHNIQUES 
From the mid 1800's to the 1920's, the medical community believed that 
opiate addiction was curable. Withdrawal followed by a few weeks of support 
123 
was considered to be sufficient for attaining this goal. By the late 1800's, 
the consensus of opinion ran in favor of the use of rapid withdrawal techniques 
as opposed to slow withdrawal. Although slow withdrawal could be 
accomplished with minimal symptomatology, rapid methods appeared to be 
more practical when one considered the tendency of addicts to either change 
their minds about detoxification or use detoxification for a few weeks as a 
91 
means of legally procurring opiate compounds. Kolb and Himmelsbach 
reviewed the major detoxification methods used from 1900-1940. As described 
below, they proved to be "...useless and even harmful treatments to control or 
91 
mitigate the severity of the symptoms...". 
Belladonna Treatment - This method utilized atropine; scopolamine in 
addition to strychnine, nitroglycerine and digitalis; or a scopolamine/purgative 
combination along with oxgall, phenacetin, caffeine, pyramidon, salicytates, 
sodium nitrate, sodium bromide, sodium bicarbonate, codeine and chloral 
hydrate. The use of these compounds was based on the theories of eliminating 
morphine stored in several body tissues including the spinal cord. In addition, 
intestinal or auto-intoxication was suggested as a cause of toxemia which led to 
withdrawal symptomatology. Kolb considered these treatments harmful serving 






Peptization and water balance was based on the theory that morphine 
coagulates protein colloids in the brain and that a peptizing agent i.e. sodium 
thiocyanate would disperse then while binding water and giving rise to 
withdrawal symptoms. The recovery of a normal distribution of endogenous 
peptizing agents signified cure. Kolb pointed out that the use of controls during 
these trials would have revealed that the patients had suffered more from the 
sodium thiocyanate, especially in terms of psychotic episodes, than they would 
have from unassisted morphine withdrawal. 
Bromide sleep treatment involved the use of sodium bromide to the point 
of delerium with subsequent revival using oxygen and strychnine. This method 
proved to be very dangerous with a death rate of two out ten. 
Lipoid Treatments were based on the belief that narcotics extracted 
lipoids from the nervous system and caused drug craving. Narcosan - a solution 
of lipoids, nonspecific proteins and water soluble vitamins was used to replace 
these supposed losses. This treatment was not only dangerous but worsened the 
patients' withdrawal symptoms. 
Endocrine Treatments were attempted when it was noted that thyroid and 
adrenal function appeared to be altered during withdrawal. Ovarian hormone 
was even used in the belief that it had a chemical structure resembling 
morphine. The presence of sympathetic symptoms and hyperglycemia suggested 
91 i Q i 
overactivity of the adrenal gland. Sakel and later Tillim 1 used insulin to 
treat withdrawal symptoms suggesting that it reestaolished the equilibrium 
which was altered by the outpouring of epinephrine as evidenced by 
hyperglycemia. Kolb suggested that hyperglycemia was not responsible for 
withdrawal - rather it was a manifestation of increased sympathetic tone. He 





Finally, immunity treatments were based on the theory that morphine 
acted as an antigen by initiating an antibody response which poisoned the 
individual and caused abstinence when morphine was withdrawn. Supposed 
antibodies were obtained from iatrogenically induced blisters or the patient’s 
own blood (autoheamotherapy) and the fluid was injected either subcutaneously 
(blister fluid) or intramuscularly (blood). These methods proved to be 
ineffective although admittedly not as dangerous as those previously discussed 
methods. 
87 
As reviewed by Kleber, since 1940 several other methods of 
detoxification have been investigated. Convulsive therapy encompasses the use 
8 8 
of metrazol, seventy per cent CC^ inhalation, electric convulsive therapy 
(ECT)^’^^^ and nonconvulsive electric shock.^ Avery^ claimed that 
metrazol induced convulsions enabled six out of ten individuals to rapidly 
decrease their morphine requirements with minimal withdrawal symptoms. 
41 
ECT was attempted in 1952 by Gallinek. Treatments for seven days produced 
attenuated withdrawal symptoms with blunting and confusion replacing anxiety 
180 
and agitation. Thigpen later studied 35 patients and claimed that ECT was 
"uniformly effective" in eliminating withdrawal symptoms. Furthermore, it 
enabled the patients to overcome the psychic and emotional aspects of 
withdrawal. On the basis of one case report in 1964, Kelman agreed with 
Thigpen concluding the ECT was able to completely suppress the narcotic 
withdrawal syndrome possibly by causing a temporary frontal lobectomy. He 
made this statement on the basis of a study by Foltz and White^ who were able 
to modify the withdrawal syndrome in monkeys with bilateral cingulumotomy, 
resection of the cingulate gyri and frontal lobectomy. Foltz suggested that this 
surgery represented possible disruption of the limbic system and modification of 
.1 - J i 
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the autonomic hyperactivity observed in withdrawal. Finally, nonconvulsive 
electric shock therapy with intravenous barbituates was used by Berkwitz^ 
who produced a complete absence of withdrawal symptoms in five subjects 
after the fifth treatment over a five day period. The lack of controls in his 
study was a major flaw. 
126 
Artificial hibernation was attempted oy Newman in 1941. Body 
temperature was lowered to 88° for two to three days after pretreatment with 
sodium pentothal and paraldehyde. Withdrawal did occur as evidenced by 
muscle tremors, restlessness and complaints of muscle pain, diarrhea, 
abdominal cramps, and nervousness post-hibernation. However, the subjects did 
not express a desire for opiates. Complications of this method included 
mesenteric thrombosis and two deaths from circulatory collapse and pneumonia. 
152 
The phenothiazine, promazine hydrochloride, was studied by Rolo who 
found this agent to elicit less drowsiness and fatigue than other phenothiazines. 
This drug enabled withdrawal to be accomplished without tension, drug craving 
or other major complications leaving the individual accessible to psychotherapy. 
58 
The use of propranolol in drug addiction was reported by Grosz in 1972. 
He found that this non-narcotic, nonaddicting drug reduced narcotic craving and 
prevented heroin induced euphoria. However, he felt that it probably was not 
useful in withdrawal since it seemed to precipitate withdrawal symptoms. 
66 
Further investigations were performed by Hollister who failed to elicit 
evidence of antagonist activity and noted that during detoxification smaller 
doses of methadone were needed when propranolol was used. However, since 
the most pronounced effects were seen in patients with mild withdrawal 
symptoms, he also doubted that it would be a useful agent. 

11 
Tennant ^^ conducted a double blind study to compare the efficacies of 
propoxyphene napsylate, a mild analgesic with less addictive potential than 
methadone, to methadone as a method of a 21 day heroin detoxification. Since 
methadone proved to be more effective in suppressing withdrawal, he felt that 
the only reason for choosing propxyphene over methadone would be because of 
its lower abuse and dependence potential. 
197 
The use of acupuncture was extensively reviewed by Whitehead who 
concluded that neither the mechanism of action nor the efficacy of acupuncture 
for any condition including addiction had been established. Suggestions have 
been made about the possibility of acupuncture inducing endogenous opiate 
136 
peptide release (see subsequent discussions). This method requires several 
treatments for the first few days and daily treatments for up to nine days. 
Whitehead claimed that the clinical trials had been inadequate because of a 
lack of controls and an inability to rule out environmental influences. 
Methadone has been the most widely used method of treating opiate 
addiction in the past 15-20 years. It is a synthetic analgesic drug developed 
in Germany during WWII which exhibited pharmacological properties resembling 
74 74 75 
morphine in animals and man. Isbell ’ studied this drug extensively in the 
late 1940's. Subcutaneously administered methadone could produce euphoria 
when the dosage exceeded 20 mg and a euphoria of slow onset which lasted up 
to 48 hours in the 30-60 mg range. Methadone both relieved and prevented 
morphine abstinence symptoms proving to be cross tolerant to morphine. 
Furthermore, it was addicting as evidenced by the precipitation of an 
abstinence syndrome when it was stopped. Tolerance was observed to develop 
pain threshold elevations, sedative effects, EEG changes, miosis and depressed 
caloric intake. Individuals on chronic doses showed psychological and 
' 
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behavioral changes resembling those of morphine addicts and after prolonged 
use a mild nonprogressive normocytic anemia appeared along with low fasting 
blood sugars; abnormal dextrose tolerance tests; EEG changes; depressed 
systolic blood pressure, respiration and pulse; and elevated body temperature. 
The abstinence syndrome was described as being mild in comparison to 
morphine-appearing three days after withdrawal, peaking at six days, and 
persisting more than two weeks. Symptoms were reported up to 60 days. Isbell 
claimed that there was less autonomic disturbance especially with respect to 
vomiting, restlessness, and diarrhea than the morphine abstinence syndrome. 
However, patients did experience weakness, fatigue, anxiety, abdominal 
discomfort, anorexia, insomnia; elevated body temperature, systolic blood 
pressure, and pulse; depressed caloric intake; weight loss and altered glucose 
tolerance tests. Although this syndrome was less severe than that of morphine 
abstinence, the persistence of symptoms was bothersome to patients. One 
person was quoted as saying. "This stuff seems like it never will turn a man 
loose. When I stop a morphine habit I start getting better on the third day and 
keep getting better every day after that. I didn't start to get sick until the 
third day off, and I'm still half sick all the time and not getting better. If I 
74 
were on the street I'd have shot up within five minutes." Isbell felt that the 
euphoric properties of this agent and its addictive potential made it 
"dangerous". He suggested that methadone be substituted for morphine and 
then tapered off over a 7-10 day period to avoid chronic use. 
116 
Martin et al repeated the extensive physiological and psychological 
studies on orally and subcutaneously administered methadone in 1973. He 
confirmed most of Isbell's findings and added the information that chronic 
methadone treatment did not cause any chest x-ray, electrocardiogram or 
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urinalysis changes. However, nonpathological elevations of SGOT which 
remained high post-withdrawal were observed as well as decreased levels of LH 
and FSH. These hormonal changes were used as a partial explanation of 
complaints of impotence. MMPI studies failed to reveal evidence of 
psychopathic deviation but the combined results of the MMPI and ARCI scales 
did show inefficiency, hypochondriasis, lethargy and decreased motivation. He 
did not agree with Isbell's observations of a paucity of autonomic symptoms. 
His patients exhibited significant withdrawal symptoms for up to three weeks 
without complete recovery for six to eight weeks. Furthermore, he suggested 
that abnormal sleep paterns and unresolved blood pressure, pupillary diameter, 
and temperature changes which persisted for up to 24 weeks, represented the 
protracted abstinence syndrome described earlier for morphine. 
The use of methadone as a method of heroin detoxification has been 
87 
studied by several groups. Kleber described a protocol in which methadone 
substitution is made during the first 24 hours to achieve stabilization. The 
morphine is then tapered either 5 mg per day or by 5 mg a day until 10-15 mg is 
reached whereupon small decrements are made as tolerated. By law, the entire 
138 
procedure cannot exceed 21 days. This issue was addressed by Raynes who 
felt that 21 days might be inadequate based on an outpatient study in which a 
mean of 22 days was required for patient controlled methadone detoxification 
schedules. 
Several studies have been conducted to determine the best method of 
201 
heroin detoxification via methadone. In 1971, Wilson studied a 90 day 
detoxification in which some participants were only outpatients while the 
others were outpatients after an initial 7 day inpatient taper to 10 mg. During 
the outpatient period the group was divided into three sections. Group I took 10 
.i 
14 
mg of methadone for 30 days, 5 mg for the next 31 days and 2 mg for the 
remaining period. Group II took 5 mg for 30 days followed by 2 mg for the 
remainder of the study. Group III received placebo. Only 2 out of 30 subject 
completed the study while only 4 out of 30 achieved zero dosage. All of the 
successful clients had returned to narcotic use within one month. Although 
Group I was more successful than Group III, which did the least well, Wilson 
concluded that he could find no benefit from low dose methadone protocols or 
prolonged detoxification techniques. Furthermore, the setting, i.e. inpatient vs. 
87 
outpatient, did not affect outcome. In discussing this last issue, Kleber felt 
that the outpatient setting risks temptation but places the patient in the 
favorable position of seeking help from his usual support systems. Inpatient 
hospitalization is very expensive and is frequently lacking from sufficient 
patient-staff interaction or psychiatric intervention. The residential 
detoxification programs or therapeutic communities do have good staffing but 
are not ideal for a polydrug abuser. In conclusion, no studies have proven that 
one method is better than the others. 
172 139 138 
Stern , Razani and Raynes conducted inpatient and outpatient 
studies which revealed that patient controlled detoxification schedules were 
more successful than physician-staff controlled protocols. The patients did not 
abuse the system and in many cases detoxified in a shorter period of time and 
with lower doses than the standard protocols would have dictated. The 
significant decrease in staff-patient tension provided a good environment in 
which to deal with individual social and emotional problems and led to increased 
self-esteem among the patients. Senay subsequently pointed out that this 
method might not be good for all addicts. In his experience, some individuals 




CAUSES OF ADDICTION AND RElAPSE 
By the 1920's, it became apparent that many addicts relapsed after 
91 
detoxification. Kolb explained this as being doe to the "psychic stresses" 
which caused opiate abuse in the first place and suggested that opiates 
"produced a seductive calm" which relieved the mental distress. The 
137 
psychoanalytic view of drug addiction was discussed in detail by Rado and 
42 
Glover. Essentially "... drug addictions were seen to be psychically 
determined, artifically induced illnesss; they can exist because drugs exist, and 
137 
they are brought into being for psychic reasons." 
Robins^ attempted to characterize narcotic abusers in 1967 by studying 
sociological variables. Her cohort consisted of 235 black males in St. Louis who 
were born between 1930 and 1934; attended a black elementary school in St. 
Louis for at least six years; resided in St. Louis between 1959 and 1964; and had 
a minimum IQ of 85. Fifty-one percent of this group had tried either heroin, 
marihuana, amphetamines or barbituates. Twelve percent had tried heroin and 
ten percent were addicted. Over seventy-five percent of heroin abusers had 
been introduced to the drug between the ages of 16 and 23. She failed to find a 
relationship between heroin use and occupational status of the guardian or 
elementary school performance. However, high school drop out rate, 
delinquency, and absent fathers were common variables in the heroin addicted 
group. 
185 186 
Valliant ’ conducted 12 and 20 year follow ups on a group of 100 
narcotic addicts who were admitted to USPHS Hospital in Lexington between 
August 1952 and January 1953. Prior to that hospitalization, forty-six percent 
of these individuals had served prison terms. Ninety-six percent had either lost 
Ji ,?*(' 
16 
a parent prior to age 16; had one parent from a different culture; or lived with 
a female family member after the age of 30. Most had begun abusing drugs in 
late adolescence and were considered to be antisocial. Ninety-four percent of 
this group were followed for a minimum of ten years or until the time of death 
showing a ninety percent relapse rate and a ninety percent rate of 
imprisonment. Forty-six percent were abstinent at the time of death or last 
contact and thirty percent had an extend abstinence period of 3-12 years. A 
nine month prison term followed by a year of parole resulted in a 15 fold 
greater abstinence rate over individuals who had only had the inpatient 
experience. Sixty-seven percent of these parolees achieved abstinence for at 
least one year. At the 20 year followup when most of this cohort were in their 
40's, the paroled subjects were still doing better. Of the original group twenty- 
three percent had died, twenty-five percent were still abusing drugs; up to 
forty-two percent had achieved stable abstinence; and ten percent were lost to 
followup. Valliant could not set an arbitrary age for the achievement of 
abstinence and concluded that employment and nonparental supervision were 
important for successful rehabilitation. 
There are several theories explaining why addicts relapse. The first 
suggests that addicts have an underlying metabolic disease^’^ which 
represents either a preexisting, possibly genetic defect, or a narcotic induced 
52 
physiological change which creates a "biochemical need". There has been no 
evidence to date of any genetic defect in narcotic addiction. Certainly, 
Martin's protracted abstinence syndrome might represent narcotic induced 
physiological derangements. In addition, opiate receptor or endogenous opiate 
peptide changes have been proposed (see opiate section for detailed discussion). 
52 
Goldstein, however, doubts a pure metabolic theory claiming that most 

17 
detoxified addicts do not appear to have unrelenting drug craving. He suggests 
that certain events such as stresses related to employment and family might be 
important in relapse. 
Goldstein tends to agree with the second theory of relapse as proposed by 
198 
Wikler. In his initial studies with decorticate dogs in 1948, Wikler 
demonstrated the development of unconditioned tolerance and dependence to 
opiate compounds. He suggested that such an unconditioned response could be 
conditioned when unconditioned stimuli were paired with the production of 
tolerance thus becoming conditioned stimuli which could initiate signs of 
199 200 
morphine withdrawal. In later articles ’ he expanded this concept stating 
that unconditioned central contra-adaptive changes develop to the agonist 
properties of opiate drugs. Concurrent pairing of initially neutral exteroceptive 
or introceptive stimuli causes them to become conditioned to produce these 
unconditioned responses even in an abstinent individual. The conditioned 
stimuli would include drug cult practices,watching others shoot up, or returning 
to old surroundings associated with drug abuse. Wikler proposed that these 
responses should be extinguished to prevent relapse (see section on antagonists). 
127 
In 1977, O'Brien actually was able to produce conditioned narcotic 
withdrawal in humans by giving naloxone as an unconditioned stimulus to 
preciptate withdrawal and pairing it with music and odors. Subsequent saline 
injections produced objective and subjective symptoms of narcotic withdrawal. 
No matter what the cause of drug abuse or relapse, Isbell's statement that 
"...withdrawal is only the first and least important step in the treatment of 




The idea that methadone might be used to maintain narcotic addicts in a 
nonwithdrawn state while they worked out psychological and social problems in 
32 
a rehabilitation program was suggested by Dole in 1965. He noted the 
existence of a moral dilemma and quoted a U.S. Senate report as saying "...We 
believe the thought of permanently maintaining drug addiction with "sustaining" 
doses of narcotic drugs to be utterly repugnant to the moral principals inherent 
32 
in our laws and the character of our people." He also addressed the issue of a 
lack of education among physicians concerning drug addiction and noted the 
tendency of the medical community to avoid contact with the addict as a 
patient. He suggested that successful treatment of drug addiction should not 
focus on total abstinence from the abused substance. Rather it "...must be 
measured by what people do, by their adjustments to the requirements of 
society, and by the capacity to enjoy the small pleasures of life and meet the 
32 
larger responsibilities ..." He believed that "A narcotic drug should be 
considered to facilitate the patients reentry into society." and that "... the 
consistent failure of efforts to rehabilitate patients after withdrawal suggests 




Dole's initial trials with methadone maintenance were conducted in 
1965. He stabilized 22 intravenous heroin abusers between the ages of 17 and 
37 on oral methadone during the first week of phase I while on ward restriction. 
This involved initial doses of 10-20 mg twice a day which were increased to 
between 50 and 150 mg per day over the following four weeks. During the last 

19 
five weeks of phase I, they were allowed both supervised and unsupervised 
excursions to school, libraries, shopping and amusements. The second phase was 
conducted as an outpatient with daily clinic contact to receive methadone doses 
and leave urine specimens. Support in finding jobs, housing, and education was 
provided at this time until phase III was reached i.e. "...a socially normal, self 
33 supporting person." 
Dole found that methadone maintenance was associated with a lack of 
narcotic craving; blockade of heroin's agonist effects; and an ability of the 
clients to place themselves in situations previously associated with narcotic 
use. Unfortunately, however, they were not immune from emotional stresses. 
Both Dole^ and Whitehead^0 have described the methadone pseudowithdrawal 
syndrome in which patients on adequate doses of methadone experience opiate 
withdrawal symptoms including malaise, nausea, yawning and sweating in the 
face of acute emotional stresses. Whitehead found that supportive 
psychotherapeutic interactions were helpful in these situations. 
The success of methadone maintenance was measured by the ability of 
Dole's patients to become socially integrated and successful at school, work and 
34 in family relationships. At three year evaluation of the program, Dole noted 
that out of 304 patients admitted, ninety-one percent had continued on 
maintenance, eight percent had been discharged for nonheroin related behavior 
problems and one percent had left voluntarily. Six or more months of 
methadone maintenance was associated with a seventy percent rate of 
employment or school attendance. None showed a need for psychotherapy 
suggesting that their antisocial behavior was a function of drug abuse not 
121 inherent psychological problems. This was confirmed by McLellan and 
186 
Valliant . Valliant found only a ten percent rate of brief psychiatric 
JfiiDCfcefc 
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hospitalizations among his cohort with only four individuals carrying a diagnosis 
of psychosis. 
79 
In 1970, Jaffe investigated the effectiveness of a totally outpatient 
methadone program which would eliminate the need for the initial six week 
hospitalization in Dole's protocol. Seventy-nine patients were followed for at 
least a year on an outpatient dose of 40 mg per day. At one year, fifty-two 
percent were still on methadone maintenance and eighty percent of this group 
were either employed, attending school or housewives. Twenty-one percent 
were no longer in treatment but maintained contact with the clinic on a weekly 
basis. 3affe also compared low daily methadone doses of approximately 36 mg 
to higher doses of 100 mg and found a larger amount of heroin abuse in the 
lower group without any significant differences in arrest rate, social 
52 
productivity or dropout rate. Goldstein on the other hand found little 
difference between daily doses of 30, 50 or 100 mg even with respect to heroin 
abuse. With a one year outpatient survivorship of sixty-seven percent, he 
claimed that 50 mg was a sufficient dose and that illegal heroin use could be 
prevented by group and individual counseling. He stated that a one year 
minimum of methadone maintenance was necessary to work on employment, 
interpersonal relationships, etc. 
109 
Current methadone maintenance as described by Lowinson consists of 
induction with 20-40 mg on the first day to achieve the goal of controlling 
abstinence. Doses are then increased by 10 mg every 3-4 days until 
maintenance levels are achieved. Her group uses 70-100 mg for older addicts 
with a longer addiction history and 30-50 mg for younger addicts. During this 
time, clients are given counseling for jobs, education, etc. After at least three 
months of daily visits and weekly urine checks, clients are considered for the 
privilege of take home doses. 
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DETOXICATION FROM METHADONE MAINTENANCE 
The decision as to when a client is ready to detoxify from methadone 
maintenance is based on the stated reason for wanting detoxification; the 
amount of time in methadone maintenance (i.e. at least a year); documentation 
of at least six consecutive months of being employed, in school or as a 
homemaker; six months without drug abuse or excessive alcohol intake; and 
86 29 
stability in emotional control and personal interactions. Cushman found 
that "...full time employment, positive motivation for detoxification, and a high 
degree of assimilation into the nondrug world" were correlated with successful 
detoxification attempts. 
In comparing slow and fast reductions in methadone dosage, reports from 
inpatient settings have described successful detoxification in short periods of 
86 29 159 
time i.e. less than one month. However, Cushman 7 and Senay 7 found 
that in inpatient settings, a slow gradual detoxification which produces a 
minimum in withdrawal symptom severity was most successful. Senay 
suggested that methadone dosage should be reduced by three percent per week 
while Cushman recommended detoxification over a minimum of six months. 
Senay emphasized the need for education about detoxification to help allay 
fears that have been built up by past withdrawal experiences. 
There is no consensus of opinion on the efficacy of blind vs. open 
techniques of detoxification. Suggestion is made that blind techniques result in 
less symptomatology at the end of detoxification when the patients are most 
• 86 
sensitive to dose reduction. Pharmacological support during this period can 
52 
consist of diazepam for hyperirritability and chloral hydrate for insomnia. 
86 
However, extra methadone doses have also proved to be useful. 
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As an estimate, only approximately fifty percent of all patients 
attempting detoxification are successful with at most a fifty percent 
QQ 
abstinence rate on long term followup. ' Reasons for failure have included 
anxiety about not being able to function without methadone, the severity of 
withdrawal symptoms or protracted abstinence. Many have turned to nonopioid 
drugs such as marihuana, cocaine and alcohol substituting an addiction to 
another. 
Prior to the discussion of more recent methods of detoxification, a 
background in the opiate receptor and endogenous peptide literature is 
necessary. 
THE OPIATE RECEPTOR 
The existence of pure opiate antagonists such as naloxone and the 
knowledge that the pharmacological activities of opiate compounds were 
stereospecific with the D(-) isomer being more potent than the virtually non 
active L (+) isomer suggested the presence of opiate receptors. The theory 
of their existence was tested by Goldstein5* in 1971. He proposed that one 
should be able to demonstrate stereospecific binding to an opiate receptor and 
was able to find subcellular stereospecific binding in the mouse brain 
homogenate but only at a level of 2%. Terenius*^, sirnon*^’ pert*^, 
167 
and Snyder subsequently were able to demonstrate stereospecific binding of 
dihydromorphine, naloxone, and etorphine to subcellular particles - specifically 
synaptosomes in the rat brain by using low concentrations of radioactive 
compounds with high specific activity, purity and affinity. This stereospecific 
activity which can be up to seventy to ninety percent, supported the 
■;:CO:or 
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existence of the opiate receptor. The fact that this binding was indeed to the 
receptor was strengthened by Snyder who compared the naloxone receptor 
binding affinities of nonopiates and opiates of different potencies and found a 
good correlation between pharmacological potency and receptor affinity. 
Further studies revealed opiate binding to be exclusive to vertebrates and 
present only in nervous tissue (i.e. CNS and smooth muscle innervation). The 
guinea pig ileum and mouse vas deferens have become the classic models used 
to study this system. 
Once the opiate receptor was identified it became possible to map its 
98 
location within nervous tissue. Some early studies by Kuhar in the rat brain 
showed regional variation with a high degree of binding in the corpus striatum 
and virtually none in the cerebellum. Kuhar and Snyder1 then mapped 
receptors in the rhesus monkey and human brain using the radioactive agonist 
dihydromorphine. The human and monkey brains showed similar distributions of 
receptors with up to a 30 fold regional variation. Most binding was present in 
the amygdala, thalamus, head of caudate, hypothalmus, periaqueductal 
midbrain, putamen and frontal poles of the cerebrum. As in the rats, little 
uptake was noted in the cerebellum. Later experiments by Simon using 
etorphine in the human brain confirmed Kuhar's findings. (For details see 
98,166,167). To determine if opiate receptors were associated with any known 
transmitters, nonadrenergic, cholinergic, and serotoninergic pathways were 
destroyed. The subsequent lack of change in opiate receptor binding led to the 
conclusion that the opiate receptor was "...not a unique component of the axons 
98 
or nerve endings of anyone of these neuronal tracts". 
Another dimension was added to the in vitro experiments described above 





vivo administration of markers. Pert used H-diprenorphine a high affinity 
antagonist and demonstrated low cerebellar binding with high binding in the 
caudate-putamen, locus coeruleus, zona compacta and substansia gelitinosa of 
the spinal cord of the rat. Extensive autoradiographic studies were later done 
by Atweh^’7 W|1Q mappecl opiate receptors in the rat brain, spinal cord, 
medulla and brain stem with etorphine and diprenorphine. 
166 
In other studies, Simon found saturable kinetics and proved a finite 
68 
number of receptor sites existed. Hbllt showed that receptor occupancy by 
naltrexone was associated with withdrawal behavior in morphine 
tolerant/dependent mice. In addition, he found that there was an in vivo 
correlation between binding and pharmacological effects by observing that 
etorphine induced analgesia could be reversed by naltrexone. The largest 
decrease in etorphine receptor occupancy corresponded to the etorphine dose 
range (3-300yg/kg) at which the analgesic effect was absent. In other studies, 
the association between opiate receptor rich regions and analgesia was 
demonstrated by injecting morphine into the brains of monkeys.^^,167 it was 
of interest that both the anatomical location and agonist pharmacological 
effects were seen in the limbic system - a region believed to control euphoria 
and attenuate reactions to pain.^^ Finally, Bird and Kuhar^’^ applied 
morphine ionotophoretically to the locus coeruleus - a region known to possess a 
high density of opiate receptors. They found a decrease in the spontaneous 
firing rate in the locus coeruleus which could be both reversed and prevented by 
naloxone. In summary, the im vitro and in vivo results had been correlated and 
the necessary criteria for demonstrating the existence of opiate receptor 
binding i.e. -saturability, stereospecificity, regional distribution and association 
of apparent binding with pharmacological effect had been met. 
.. c ■ ti ■ & £: 
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ENDOGENOUS OPIATE PEPTIDES 
The convincing identification of an opiate receptor led to speculation 
3 
about the existence of an endogenous opiate substance. Akil and Mayer’s 
findings that electrical stimulation of the central grey of rates produced 
analgesia which could be partially reversed by naloxone was suggestive of an 
endogenous opiate compound. In 1975, Hughes demonstrated the existence of 
an endogenous substance from pig brain which acted as an agonist in the mouse 
vas deferens and guinea pig ileum and produced naloxone and naltrexone 
reversible inhibition of electrically induced contractions. Terenius*'7'7 and 
129 
Pasternak identified a compound in the calf and rat brain which acted like 
an endogenous ligand by inhibiting the opiate receptor binding of naloxone and 
dihydromorphine. In addition, it had an anatomical distribution similar to the 
opiate receptor, showed inhibition of binding with sodium and enhancement with 
magnesium as expected for an agonist;130,165,166,167,168 ancj was iocatecj jn 
72 
synaptosomal fractions. Hughes further characterized the pig brain extract 
which he named enkephalin as being composed of two parts peptides differing in 
the carboxyl amino acid. Named met-enkephalin and leu-enkephalin, these 
peptides showed naloxone inhibited agonist activity the guinea pig ileum and 
mouse vas deferens. The calf brain extract was studied by Simantov^""’ 
who found it to be met-enkephelin and leu-enkephalin - the same peptides 
identified by Hughes in the pig brain. 
Another opiate compound was identified in bovine pituitary extracts by 
Teschmacher and Goldstein^^ and in crude ACTH extract by Cox^. This 
compound exhibited the agonist properties of naloxone reversible inhibition of 
electrical stimulation of the guinea pig ileum and mouse vas deferens; inhibited 
ir Tj •; 
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binding of etorphine at synaptic membranes; and showed sodium inhibition 
effects. Furthermore, it resembled 3-lipotropin (3-LPH) - a pituitary compound 
identified in 1964 by Li^4,105 -n ^CTH extract from sheep pituitary gland. 
Cox ^ further characterized this peptide showing that 3-LPH (amino acids 1-91) 
had no opioid activity while the 61-91 fragment which contained the 61-65 
sequence of enkephalin did possess opioid activity in the guinea pig ileum as 
well as stereospecific inhibition of etorphine binding in brain homogenates. 
Bradbury confirmed this finding. Other investigators identified a-endorphin 
(amino acids 61-76) and y- endorphin (amino acids 61-77) as active fragments. 
166 
The 61-91 fragment referred to as 3-endorphin is the most active. The 
discovery of an inactive large peptide chain containing smaller active 
25 
fragments led Cox to propose that 3-LPH might be a prohormone similar to 
proinsulin. 
Attempts at mapping the distribution of these endogenous compounds by 
Watson, 192,193 gjoom> 12 5ny(-jer> 168,169 ancj £^36 s|nowec| a predominantly 
different distribution for 3-endorphin and the enkephalins. Attempts at 
selective mapping of met-enkephalin using antisera to met-enkephaiin which did 
not cross-react with leu-enkephalin or endorphin failed to demonstrate any 
differences in the CNS distribution of the two enkephalins. Enkephalin was also 
demonstrated in peripheral regions by Schultzberg^'7 who found enkephalin 
immunoreactivity the sympathetic ganglia of the guinea pig and rat. The 
different neuronal pathways and origins of the endorphin and enkephalins were 
suggested by the fact that unlike the endorphins, the enkephalin distribution 
appeared to be parallel to that found for the opiate receptor. Furthermore, 
antisera to ACTH stained 3-endorphin/3-LPH cells but not enkephalin cells 




enkephalins were not despite some common amino acid sequences. At this 
point, however, the relationship between met enkephalin and 3-endorphin is far 
192 
from certain especially since there is some overlap in their distribution. 
The next studies turned to the role of these compounds as endogenous 
72 
opiate agonists. Hughes' initial studies had demonstrated the effects of the 
enkephalins on peripheral organs finding met-enkephalin to be 20 times as 
potent as morphine while leu-enkephalin was 10 times as potent in the mouse 
vas deferens. In the guinea pig ileum, model met-enkephalin was as potent as 
morphine and leu-enkephalin possessed one-fifth the potency of morphine. 
25 
Cox demonstrated 3-endorphin agonist activity in the guinea pig ileum finding 
it to be equipotent to met-enkephalin. Lord^^ found that 3-endorphin was 
equipotent in the guinea pig ileum and mouse vas deferens and inhibited leu- 
enkephalin and naloxone equally well in the guinea pig brain. Further 
comparison of the endorphins and enkephalins showed a-endorphin, met- 
enkephalin and leu-enkephalin to be more potent than 3-endorphin in the mouse 
vas deferens while ot-endorphin and leu-enkephalin were less active than met- 
enkephalin and 3-endorphin. The later two peptides were equipotent in the 
guinea pig ileum. 
162 
Turning to central effects, Simantov found that both met- and leu- 
enkephalin decreased dihydromorpnine binding in the rat brain equally well 
while met-enkephalin was twice as potent as leu-enkephalin in decreasing 
naloxone binding. In addition, the effect of sodium in reducing agonist binding 
was two times greater for leu-enkephalin than met-enkephalin implying that 
met-enkephalin may have more antagonist properties. Chang,^ Bhscher,^ 
Bradley^ and Graf^ studied the properties of enkephalins in both brain 
20 
homogenates and after direct injection into brain tissue im vivo. Chang 




showed that met-enkephalin had one-half the affinity of morphine while leu- 
enkephalin had one-seventh the affinity in opiate receptor binding studies. 
Direct injection of the enkephalins and morphine into the periaquaductal grey 
of rats showed the leu-enkephalin had virtually no analgesic effect and met- 
enkephalin was much less potent than morphine requiring high doses to produce 
14 
short lived naloxone reversible analgesic effects. Bradley injected met- 
enkephalin into single neurons in the rat brain stem and found that met- 
enkephalin had naloxone reversible depression of seventy percent of neurons 
17 54 
which were also depressed by etorphine and morphine. BUscher and Graf 
performed intracerebroventricular injections and confirmed the fact that both 
enkephalins have faster acting and shorter lived analgesic actions than 
morphine. Morphine analgesia was greater than met-enkephalin which was 
greater than leu-enkephalin. 
The evanescent action and weak potency of the enkephalins was thought 
20133 133 
to be due to their rapid enzymatic degradation in the brain. ’ Pert 
synthesized the compound |p Ala^-met-enkephalinamide which proved to be 
less susceptible to degradation and produced longer lived analgesia when 
26 
injected into the rat Drain. Craves criticized the use of such analogues 
claiming that their antinociceptive potency is due to some undefined property. 
He found differences from the natural peptides in lipid partitioning, potency in 
both the guinea pig ileum and mouse vas deferens models and interactions with 
brain opiate receptor sites. Furthermore, he questioned the theory of rapid 
enzymatic degradation calculating the half life of met-enkephalin in vivo to be 
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Studies on ^endorphin were conducted by Tseng, ’ Loh, 
3acquet,77Bloom,12 and Graf5\ dacquet and Loh injected 3-endorphin into the 
periaqueductal grey of rats and found that 3-endorphin had greater naloxone 
blocked/reversible analgesic activity than morphine. Tseng and Graf performed 
both intravenous and intracerebroventricular injections showing the production 
of naloxone reversible analgesia with S-endorphin analgesia greater than 
morphine which was greater than met-enkephalin. The 3-endorphin analgesia 
was different than enkephalin in that it had a longer latent period and duration. 
Bloom noted naloxone reversible electroencephalogram (EEG) changes in rats 
treated with intracerebroventricular 3-endorphin. These EEG changes were 
more pronounced for 3-endorphin then met-enkephalin. Morphine-like tolerance 
and dependence were produced by 3-endorphin as demonstrated by naloxone 
precipitated withdrawal symptoms, cross tolerance to morphine and attenuation 
of analgesic and EEG responses. ^ 2,107,183 development of 
tolerance/dependence and naloxone induced withdrawal symptoms has also been 
169 
observed with enkephalin. 
Nonanalgesic responses to the endogenous peptides were studied by 
12 1 o 3 "I 
Bloom, Tseng, dacquet/ and Wei^^. 3-endorphin appeared to elicit 
more pronounced behavioral responses than the enkephalins or a-endorphin 
during intracerebral injections. Naloxone revisible catatonia, sedation, and 
rigidity were seen with S-endorphin while morphine was more often associated 
with hyperactivity. Finally, the enkephalins produced an increase in locomotor 
activity not observed with 3-endorphin. 
The apparent naloxone reversible analgesia produced by the endogenous 
peptides led investigators to postulate that naloxone should alter pain 
perception in humans by competing for receptor sites with these supposed 
. 
30 
endogenous ligands. The studies which had supplied some indirect evidence for 
136 
a role of endogenous peptides in pain perception were Pomeranz who 
demonstrated naloxone reversible analgesia in mice during acupuncture; 
120 
Mayer who showed that naloxone antagonized the elevated pain threshold in 
69 
humans subjected to acupuncture; and Hosobuchi who found naloxone 
reversible attenuation of pain in humans during electrical stimulation of the 
brain. However, Grevert^6 was not able to find any naloxone induced 
difference in the pain ratings of individuals subjected to ischemia and cold 
16 
water immersion. Buschbaum postulated that there might be individual 
variation in endogenous peptide levels. He divided people into pain sensitive 
and insensitive groups and demonstrated that naloxone administration to the 
pain insenstive group increased the perception of pain produced by electric 
103 
shocks. Levine went one step further and showed that naloxone could 
increase existing pain from dental extraction. He concluded that noxious 
stimuli might precipitate the release of endogenous peptides which were then 
antagonized by naloxone. 
MULTIPLE OPIATE RECEPTORS 
The differences in enkephalin, endorphin and morphine binding in the 
mouse vas deferens and guinea pig ileum preparations; the varied behavioral 
responses elicited by these compounds; and the existence of pure antagonist, 
pure angonist and mixed antagonist compounds suggested the existence of 
multiple heterogenous opiate receptors with compounds acting at several 
different sites. Martin did extensive studies on the chronic spinal dog and 
suggested the presence of three receptors which produced different 
3 . . i . 
' 
j, ■ , -,7 . •:< xoIen ?» j 
■ 
31 
physiological responses. These included y for the agonist morphine; k for the 
mixed antagonist/agonist ketocyclazocine which neither suppressed the 
morphine abstinence syndrome nor precipitated significant withdrawal 
108 
symptoms; and <7 for SKF 10047. Lord analyzed guinea pig brain 
homogenates and the mouse vas deferens and guinea pig ileum models finding 
that the guinea pig ileum contained y and k receptors with a predominance 
of y receptors while the mouse vas deferens had 6 and y receptors with a 
predominance of 6 receptors. The presence of the fourth receptor, <3 , was 
also suggested by Kosterlitz who demonstrated that enkephalin and $- 
endorphin can interact with the y receptor in the guinea pig ileum but will show 
predominantly 5 receptor interactions in the mouse vas deferens. Schulz 
was able to separate the y and 6 receptor activities in the mouse vas deferens 
2 5 
by using sufantanyl, a selective y receptor agonist, and DAla Dleu enkepnalin a 
5 receptor agonist. He demonstrated selective tolerance for each receptor 
without evidence of cross tolerance. The 5 receptor in the mouse vas deferens 
96 resembled the leu-enkephalin receptor in guinea pig brain and the presumed 
£ 21 almost pure 0 population in neuroblastoma cells . The possibility of a fifth 
62 receptor has been noted in the rat vas deferens. This receptor exhibits 
excellent 6-endorphin agonist activity, slight enkephalin activity and negligible 
178 
morphine activity. In another classification scheme, Terenius suggested 
that opiate receptors could be broken down into morphine, antagonist and 
opiate peptide sites with the antagonist properties of the compounds 
determining their affinity for these sites. Indeed, Synder ’ demonstrated 
that the greater the antagonist properties of a compound the greater its 
affinity for met-enkephalin sites as opposed to naloxone/dihydromorphine 
labeled sites. Finally, Herling demonstrated interspecies variation in opiate 
rfoli ' • 
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receptor heterogeneity. Despite all the evidence suggesting the existence of 
multiple receptors one must keep in mind the excellent point made by Adler ^ 
who suggested that we will not be able to prove the existence of these 
receptors until selective antagonists are discovered. 
The classification scheme can be summarized as follows: 
1. p CNS, guinea pig ileum, mouse vas deferens 
2. K CNS, guinea pig ileum 
3. O CNS 
4. & mouse vas deferens, neuroblastoma, CNS-enkephalin 
5. #5 rat vas deferens 
(modified from Terenius^S) 
THEORIES ABOUT OPIATE TOLERANCE AND DEPENDENCE 
There are several theories concerning the possible biological mechanism 
and consequences of opiate tolerance and dependence. The first theory 
postulates that there is a change in the number or the affinity of opiate 
receptors. The results of these experiments have provided conflicting results. 
132 
Pert found an increase in opiate receptor binding with chronic morphine 
pellet implantation. However, the same amount of binding was seen two hours 
post-implantation as at 108 hours. This was a time period during which 
tolerance had increased by a factor of five. Furthermore, the maximal increase 
in binding occurred within five minutes which was much sooner than tolerance 
and dependence had peaked. Pert also made the observation that antagonists 
• . '■ - 
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were up to 1000 times more potent in increasing receptor binding than agonists. 
In fact, the greater the antagonist properties of a compound the greater its 
effect. These findings have been confirmed by Herz,^ Lahti, Schultz, 
and Tang^^ who observed an increase in receptor number not affinity following 
antagonist treatment. Since changes in the sodium concentration of the assay 
abolished the receptor enhancement by agonists, Pert concluded that there 
were no receptor changes in opiate tolerance/dependence. He interpreted his 
results as demonstrating the displacement of endogenous opiates by exogenous 
opiates which would make the receptors available for in vitro labeling. 
166 67 3s 
Simon, HOllt, and Dum also failed to demonstrate a change in opiate 
receptor binding or affinity in tolerant vs. naive animals using brain 
homogenates with iri vivo and in vitro techniques. The only studies which did 
31 
find opiate receptor changes were those conducted by Davis who used brain 
slices as opposed to brain homogenates. She documented a decline in opiate 
binding secondary to decreased affinity which persisted for up to four days 
after withdrawal in rats chronically treated with morphine and etorphine. 
The second theory suggests that chronic exposure to exogenous opiates 
would result in a decline in the level of endogenously produced peptides possibly 
by feedback inhibition and/or an increase in endogenous peptide 
inactivation^ 10. Using a sensitive specific radioimmunoassay, Childers'0 failed 
to find an effect of chronic morphine treatment in rats on met-enkephalin or 
Q 
leu-enkephalin levels. Bergstrttm, on the other hand, found no effect on 
enkephalin levels in rats after a single acute dose of morphine. However, 
chronic treatment while failing to show a change within two hours of the last 
dose, did show decreased enkephalin levels at 24 hours. This was followed by a 
return toward baseline with insignificantly decreased enkephalin levels as 
• i 
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compared to the control and two hour group at 48 hours. The maximum decline 
in brain enkephalin levels corresponded to the peak in withdrawal 
symptomatology suggesting that the abstinence syndrome may represent an 
imbalance in the enkephalin system. Although Childers did precipitate 
withdrawal in his studies using naloxone, he measured enkephalin levels within 
60 minutes which possibly was too short a period of time according to 
Bergstrbm's study. To date, no one has developed a method to measure 
enkephalin turnover which certainly could be affected. The possibility that 
enkephalin is more rapidly degraded in chronic morphine addiction is suggested 
by Malfroy.^^ He demonstrated a selective increase in the activity of a high 
affinity enkephalin degrading peptidase in the particulate fraction of mouse 
striatum following chronic morphine treatment. The distribution of this 
peptidase showed regional heterogeniety paralleling the previously determined 
enkephalin peptide distribution. 
Other researchers have suggested that endorphin levels may be affected 
by chronic opiate exposure. The association between ACTH and 3-endorphin 
was noted during mapping studies as previously described. Guillemin later 
demonstrated the concomitant secretion of ACTH and 3-endorphin from the 
pituitary gland of rats. Plasma and pituitary concentrations of these 
compounds paralleled each other making the theory of 3-Hpotropin as a common 
187 
precurser to ACTH and 3-endorphin plausible. Subsequently Volovka found 
that naloxone increased plasma ACTH and cortisol levels in men who did not 
have a history of opiate addiction and suggested that the endogenous opiates 
which were presumably displaced by naloxone might regulate ACTH and by 
association endorphin/3-lipotropin secretion through feedback inhibition. 
Ho^’^ went on to demonstrate that rats addicted to morphine for three or 
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more months had less 3-endorphin immunoreactivity in their brain tissue than 
controls. He also demonstrated that both serum ACTH and serum g- 
lipotropin/g-endorphin levels in heroin addicts were lower than controls. 
hQ 
Finally, Gold showed that methadone infusion can lower plasma cortisol 
levels in humans. Further studies with methadone addicts who had undergone 
clonidine detoxification showed that naltrexone failed to elicit the marked rise 
in plasma cortisol levels as observed in Volovka's normal human subjects. In 
fact, the small increase observed was statistically insignificant when compared 
with baseline values. Gold proposed that these results reflected decreased 
ACTH/g-lipotropin/g-endorphin reserve levels in methadone addicts as 
compared to controls and that the withdrawal syndrome may represent an 
inadequate endogenous endorphin supply which has been suppressed by 
exogenous opiates. This low reserve would become apparent when the 
exogenous opiate supply was abruptly removed. 
The third theory concerns the role of central nonadrenergic neurons in 
withdrawal and is the basis of the clinical trials with clonidine. An 
associationbetween increased sympathetic activity and opiate withdrawal was 
noted at least as far back as 1938. Kolb believed that 
... the functions of the sympathetic nervous system 
are depressed by morphine. In chronic users there is 
a reaction against this depression that tends to 
restore the functions to normal... When morphine is 
withdrawn the reactive mechanism designed to 
counteract poisonous doses of it continues to work... 
This causes powerful stimulation of certain 
functions under the control of the sympathetic - 
hence, the sweating, goose-flesh... increased blood 




As will become evident in the discussion to follow, recent research has shown 
that Kolb was closer than others before him in proposing a satisfactory 
mechanism of drug addiction and withdrawal. 
As reviewed by Langer,*^* the noradrenergic transmission system is 
believed to be controlled by a and 3 receptors located both pre- and 
postsynaptically. Nerve stimulation causes noradrenaline release which at 
low concentrations would activate presynaptic 3 receptors and further 
increase noradrenaline release via cyclic AMP. However, when the 
concentration of noradrenaline in the synaptic cleft reaches a certain 
threshold, negative feedback inhibition would become important and 
noradrenaline would activate presynaptic a receptors and inhibiting 
noradrenaline release. This action is believed to be mediated through 
reduced availability of calcium for stimulus -secretion coupling.Based on 
studies outside the CNS with various receptor antagonists and agonists, 
Langer demonstrated that pre- and postsynaptic a receptors were different. 
As such he proposed the classification of a 1 receptors as postsynaptic 
receptors which controlled responses at the effector organ and a 2 as 
presynaptic receptors which mediated noradrenaline release during nerve 
stimulation.**** 
The development of clonidine, a presumed a 2 receptor agonist, has 
aided in much of the research on a receptors. Clonidine's actions on a 
receptors were noted in experiments showing that it depressed the 
electrically stimulated release of norepinephrine from rat cerebral cortex 
slices and mouse atria and decreased norepinephrine turnover in the 
171 37 18 
brain. ’ ’ The question of whether clonidine is a pre- or postsynaptic a 
agent has been hotly debated. Haeusler^ has argued for a postsynaptic 
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location while Starke ^ found that clonidine can act at both pre- and 
postsynaptic sites but will act preferentially at the presynaptic site. In 
general, clonidine is considered to be an a2 receptor (i.e. presynaptic). Part 
of the problem in the characterization of clonidine lies in the controversy 
203 
about the location of a 2 receptors in the brain. Young recently 
attempted light microscopic autoradiographic localization of a 2 receptors in 
the rat brain but failed to resolve the issue. He concluded that the a2 
receptors might be located both pre- and postsynaptically in the CNS. 
30 
In studies aimed at mapping monamines in the CNS, Danlstrbm 
demonstrated the presence of a tightly packed group of nerve cells in the 
locus coerulus (LC) wnich were characterized by being almost entirely 
composed of norepinephrine. The LC is a nucleus in the anterior pons which 
92 94 
has projections to the ipsilateral cerebral cortex, hippocampus ’ and 
19 19 
cerebellum and receives projections from the medulla. Studies by Korf, 
Aghajanian and Roth demonstrated that electrical stimulation of the LC 
increased levels of MHPG sulfate, a norepinephrine metabolite, in the cortex 
and hippocampus of rats. Conversely the destruction of the LC caused an 80% 
reduction in norepinephrine levels and a 70% reduction in MHPG sulfate in 
92 
the ipsilateral cortex and hippocampus. They proposed that since 
stimulation of the LC caused a reduction in cortical norepinephrine (NE), 
impulses originating in the LC and flowing through adrenergic pathways must 
cause an increased turnover in NE stores. Further evidence of increased 
turnover lay in the demonstration that stimulation induced increases in NE 
turnover could be abolished by transection of the dorsal pathways from the 
LC to the cortex and hippocampus. Thus the NE content of the cortex 
93 
appeared to be related to LC activity. 
■ 
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Among the multiple presynaptic receptors in noradrenergic nerve 
endings is the opiate receptor. This receptor can inhibit transmission at 
adrenergic nerve endings when acted upon by opiate receptor 
agonists. A possible relationship between the LC and opiate 
compounds was proposed with the discovery that it contained a high density 
of opiate receptors^ as well as 3-lipotropin / 3-endorphin^ and met- 
99 193 94 202 
enkephalin reactivity ’ . Furthermore, studies by Korf, Young, 
99 11 
Kuhar, and Bird demonstrated that both morphine and met-enkephalin 
could produce selective naloxone reversible LC depression. 
18 
The locus coeruleus also possesses a receptors. Cedarbaum found 
that the a antagonist piperoxane increased the rate of spontaneous LC firing 
in rat brains while clonidine, norepinephrine and epinephrine reduced the 
level. Furthermore, piperoxane was able to prevent and/or reverse the 
clonidine inhibition. Norepinephrine and epinephrine inhibition was 
postulated to be through actions at presynaptic a receptors which act as 
autoreceptors as per Langer. The LC a receptors were further characterized 
by Cedar bam 19 as being of the a 2 type since the postsynaptic a agonist 
phenylephrine had only weak inhibitory effects on LC firing. Furthermore, 
clonidine proved to be a the most potent of the a agonists in the LC. 
203 
Young's autoradiographic studies were consistent with Cedarbaum's 
results. He found a predominance of a 2 receptors in the LC with only very 
low densities of a 1 receptors. 
2 
Agnajanian was able to convincingly demonstrate that the a and 
opiate receptors in the LC were separate despite having similar qualitative 
actions. Using single cell recording and microionotophoretic techniques he 
found that acute morphine injections produced naloxone inhibited LC 
. 
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depression and that clonidine was able to depress LC activity even in the 
presence of naloxone blockade. Similarly, blockage of a receptors with 
piperoxane inhibited clonidine's LC depressant actions but did not alter 
morphine effects. He went on to demonstrate the development of tolerance 
to morphine, finding that LC firing was decreased 24 hours post-morphine 
pellet implantation in the rat brain but had returned to baseline within 4-5 
days. Finally, naloxone induced withdrawal in morphine dependent rats was 
accompanied by clonidine reversible increased LC firing which was consistent 
with the hypothesis of a hyperadrenergic state during withdrawal which might 
be effectively treated with the nonopiate compound clonidine. Further 
evidence for this later idea came from Crawley, Laverty and Roth who 
demonstrated that clonidine reduced the increase in NE turnover in the brains 
102 
of morphinized rats undergoing naloxone induced withdrawal. This NE 
turnover appeared to be associated with LC activity since MHPG levels in 
brain regions innervated by the LC were increased during naloxone 
precipitated withdrawal. It was of interest that clonidine also reversed these 
, 27 
changes. 
Studies by Redmond and Huang have concentrated on the role of the 
locus coeruleus in nonhuman primates. Their findings would presumably be 
applicable to man. Initial work on the stumptail macaque confirmed the 
findings already described for other animal systems. Namely, destruction of 
the LC lowered MHPG and norepinephrine levels in the cortex and 
hippocampus with seventy-one to eighty-one percent depletion following a 
single lesion and eighty to ninety percent with bilateral lesions. Therefore, 
most of the norepinephrine in the macaque cerebral cortex appeared to come 
from the LC7® In addition, naloxone treated morpnine tolerant primates 
■ 
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showed increases in brain and plasma MHPG levels as would be expected 
during the hyperadrenergic withdrawal state. 
In subsequent studies, this group investigated the effects of LC 
stimulation^^, destruction^, and piperoxane^’administration noting 
that LC stimulation and piperoxane produced similar behaviors which 
resembled primate reactions to human threats and opiate withdrawal while 
destructive lesions attenuated these benaviors. The behaviors included 
yawning, chewing, scratching, startling, struggling, wringing of hands, pulling 
of hair or skin, tongue movements, chair grasping, self mouthing, pupillary 
dilatation, piloerection, increased blood pressure, increased heart rate, and 
143 
alerting. Intravenous clonidine was found to either depress or block the 
43 71 
behavioral effects of LC stimulation and piperoxane ’ while naloxone was 
able to reverse the depressant affects of morphine and met-enkephalin on 
142 
these induced behaviors. Thus, the LC appeared to be involved in 
140 
"anxiety-fear" behavior and possibly the hyperadrenergic state of opiate 
143 
withdrawal. 
Using the information discussed above and some more recent 
developments, several authors have hypothesized about the events which may 
occur during morphine dependence, withdrawal and post-detoxification 
states. Llorens^^ found that chronic morphine treatment in rats caused 
hypersensititivity to norepinephrine with a fifty percent increase in cyclic 
AMP stimulation and a nineteen percent increase in the number of 3 
adrenergic receptors. This was not accompanied by a change in their 
affinity. He postulated that morphine causes a "disuse hypersensitivity" such 
that the depressant effect of morphine on noradrenergic transmission is 
compensated for an increase in the number of postsynaptic 3 receptors. In 
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abstinence, inhibition of noradrenergic neurons is abruptly stopped flooding 
an excess number of receptors with a nondepressed quantity of transmitters. 
This adds to LC hyperactivity and possibly as Gold suggests^'7 a lack of 
endogenous opiate peptides to create the state of increased sympathetic 
125 
activity seen during withdrawal. Nathanson confirmed Llorens' findings 
by demonstrating postsynaptic supersensitivity in primates. He went one step 
further suggesting that the noradrenergic hyperactivity in withdrawal might 
cause a reciprocal subsensitivity of noradrenergic receptors post withdrawal. 
He found that both morphine withdrawal and piperoxane antagonist actions 
produced a fall in adenylate cyclase activity below that seen in either 
controls or the chronic morphine state. He suggested that this is consistent 
with down regulation or Q receptor subsensitivity and might explain the 
protracted abstinence syndrome described by Martin. 
38 
The studies oulined above as well as those of Fielding who 
demonstrated clonidine suppression of the morphine abstinence syndrome in 
rats led to investigations into the use of clonidine for the human opiate 
withdrawal syndrome. 
CLINICAL APPLICATIONS OF CLONIDINE 
Clonidine was synthesized in 1962 and initially used to treat patients with 
134 
moderate to severe hypertension. Preliminary studies on animals had shown 
that intravenous injections produced a transient increase in blood pressure 
which was believed to be secondary to peripheral a adrenergic stimulation. 
This was followed by hypotension and bradycardia with decreased cardiac 
output and occasionally decreased peripheral resistance. Increased vagal 
* 
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activity was also noted and felt to contribute to the bradycardia. The lack of a 
tachycardic response suggested the presence of a agonist activities without 3 
agonist actions.90 These cardiovascular effects appeared to be mediated by 
depressed sympathetic activity since depletion of sympathetic amine stores 
40 
either abolished or diminished clonidine's hypotensive actions. Furthermore, 
these effects appeared to be centrally based at the level of the medulla, 
203 
possibly in the nucleus solitarius, since intracisternal injections were more 
effective than intravenous ones and transection below the level of the medulla 
abolished clonidine's actions.^’Finally, clonidine was noted to have 
renal actions suppressing renin secretion either by decreasing centrally 
146 
mediated renal sympathetic tone or acting on a adrenergic receptors in the 
194 
kidney parenchyma itself. Lowered renin levels appeared to cause lower 




In man, the onset of clonidine's antihypertensive effect is seen at 30 
minutes reaching a maximum at 2-4 hours and lasting up to 24-26 hours. Side 
effects at usual dosages of 0.2 - 2.4 mg/day include transient sodium retention, 
drowsiness, lethargy, dry oral mucosa and potentiation of insulin induced 
hypoglycemia. Clonidine was also noted to have a withdrawal syndrome when 
134 147 173 
abruptly stopped ’ * with symptoms of insomia, anxiety, nervousness, 
headache, abdominal pain, nausea and vomiting occurring within 18-24 hours 
and elevated blood pressure in 24-48 hours. This is associated with increased 
levels of plasma norepinephrine and urinary catecholamines at 24-72 hours and 
is thought to be secondary to hyperactivity of the sympathetic nervous system. 
It is seen mostly in individuals whose daily doses exceed 1 mg and can be 
prevented by a 2-4 day taper. 
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CLONIDINE TRIALS IN HUMAN OPIATE WITHDRAWAL 
Initial studies on the use of clonidine were conducted by Gold, Redmond, 
and Kleber^’^’^ in 1978 on five individuals who had taken methadone for at 
least six months in the 15-50 mg dose range. After an initial 36 hour period of 
methadone abstinence, they were treated as inpatients on a locked ward in a 
placebo controlled study utilizing initial clonidine doses of 5yg/kg. Withdrawal 
symptom ratings were conducted every 30 minutes and vital signs were closely 
followed. A reversal of baseline withdrawal symptoms was observed within 90 
minutes with both systolic and diastolic blood pressure drops from 124/85 to 
106/69 manifested by 120 minutes. All participants expressed subjective relief 
and related that clonidine had stopped the sensation of "kicking" which had been 
present on admission. This inpatient study was followed by a week long 
outpatient trial of 5yg/kg twice a day. Patients were observed daily failing to 
show any apparent change in abstinence ratings. Most complaints consisted of 
sluggishness and insomnia. The withdrawal symptoms did not recur when 
clonidine was stopped nor were there any manifestations of the clonidine 
withdrawal syndrone. 
A more sophisticated inpatient study was later conducted by this same 
184 
group on nine opiate addicts (7methadone, 2 dilaudid). This was a double 
blind study where patients were told that they would be given methadone, 
clonidine or placebo at 9AM, 1PM, 5PM, and 9PM. Clonidine was started at 
doses of 1.5-5 yg/kg when mild abstinence appeared and increased appropriately 
for symptomatology stopping when systolic blood pressure fell below 85. All 
patients were started on clonidine within 36 hours of methadone withdrawal and 

44 
reached an average peak dose of 13.4pg/kg/day. Tapering of clonidine over a 2- 
5 day period was conducted when withdrawal symptoms had been absent for 24- 
48 hours. The clonidine therapy lasted for eight days and naltrexone was safely 
begun in all participants on the third post-clonidine day without a recurrence of 
abstinence symptoms. Everyone stated that the abstinence symptoms were less 
severe with clonidine than in other detoxification attempts. Symptoms which 
were most prominent included aching of bones and muscles and insomnia. There 
were no syncopal episodes or evidence of severe bradycardia or hypotension. 
Thus clonidine appeared to safely suppress the onset of withdrawal symptoms. 
Furthermore, followup of this group at three months did not reveal the presence 
of any physiological symptoms. 
The clonidine withdrawal technique was refined by Gold^ in a 14 day 
inpatient study which included ten participants with methadone maintenance in 
the 10-50 mg range. Successful detoxification could be achieved with initial 
doses of 6 pg/kg two times per day for the first day after 36 hours of 
abstinence. This was followed by a nine day course of 17 pg/kg/day divided in 
three doses and a taper over days 11, 12, and 13 by fifty percent per day. 
Naloxone challenges on day 14 were negative for all patients indicating 
successful detoxification. Clonidine doses did have to be titirated individually 
in this study as dizziness became an occasional problem requiring single doses 
to be held. One further study by Gold proved that this method could be 
applied to individuals on low (14 mg), medium (50 mg) and high (75 mg) doses of 
methadone. All were able to achieve successful detoxification although the 50 
mg and 75 mg groups experienced more symptoms. 
188 190 
Washton and Resnick ’ have conducted successful outpatient 
studies. Initial studies included 70 patients who had methadone habits in the 5- 
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40 mg range or a heroin habit in the $10-$ 150 range. Twenty patients were 
treated with clonidine and a methadone taper of 5-10 mg per week. The others 
were treated with just clonidine following abrupt termination of methadone or 
heroin. Doses of clonidine were started at 0.1 mg every four to six hours for 
the first day with increases of 0.1-0.2 mg to a 1.2 mg maximum each day for 
ten days. Doses were individualized based on blood pressure and 
symptomatology. They found that abrupt cessation of opiates proved to be 
more successful than methadone taper in conjunction with clonidine 
detoxification and stressed the importance of individual dose determination to 
minimize symptoms of lightheadedness and lethargy. In addition, they found 
that a clonidine taper was necessary to prevent headaches and return of 
withdrawal symptoms. 
189 
In another study, this group compared outpatient clonidine 
detoxification to a slow methadone taper of 1 mg per day. Neither method 
appeared to be more successful. The only difference noted was that clonidine 
treated patients experienced withdrawal symptoms during the first days of 
withdrawal while the methadone taper participants did not have symptoms until 
the end of the study when the methadone doses were very small. 
22 
The latest study by Charney and Kleber was conducted on 21 patients 
with a methadone maintenance range of 10-20 mg and demonstrated an eighty 
percent success rate. The protocol involved 10-11 days of individually adjusted 
clonidine doses with a mean peak of 6.8 pg/kg and a range of 10-22.2 pg/kg on 
day five when symptom ratings were maximal. Doses were given three times 
per day and tapered over the last 3-4 days of treatment without evidence of a 
reemergence of withdrawal symptoms. Statistically significant but clinically 
insignificant changes were recorded in standing blood pressure while the 
. 
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predominant withdrawal symptoms included anxiety, restlessness, insomnia and 
muscle aching. 
LOFEXIDINE 
The major drawbacks of clonidine therapy are its antihypertensive and 
sedative actions. Recently another a agonist, lofexidine, was tried because it 
demonstrated less hypotensive and sedative effects, and was shown to suppress 
withdrawal in morphine dependent rats.^^ Washton and Resnick^ conducted 
an outpatient trial on 15 methadone addicts whose maintenance doses were 10- 
25 mg. Loxefidine was begun while on methadone and doses were individually 
determined according to symptomatology. Methadone was stopped on the 
second day and lofexidine was continued for a total of eleven days including a 
taper. On day eleven, a naloxone challenge test was given to all participants 
who had remained abstinent and naltrexone therapy was started if the challenge 
was negative. These subjects showed no evidence of oversedation, 
lightheadedness, blood pressure drops or uncontrolled abstinence symptoms. As 
with clonidine, insomnia, lethargy, and muscle and bone pain still persisted. 
Washton and Resnick suggested that the less prominent hypotensive and 
sedative effects might make lofexidine preferable to clonidine in opiate 
withdrawal. The usefulness of this agent awaits further clinical trials. In 
addition, its availability is a problem. Unlike clonidine, it is not currently an 
FDA approved drug. The company has not attempted to seek this approval 
because of its relatively poor antihypertensive effects. 
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OPIATE ANTAGONISTS 
Based on Wikler's conditioning theories, research was directed toward the 
use of opiate antagonists in extinguishing possible conditioned withdrawal 
responses from exteroceptive and interoceptive stimuli as well as helping to 
minimize drug seeking behavior during the protracted abstinence syndrome 
described by Martin. Original studies with nalorphine, a mixed 
antagonist/agonist, noted its ability to precipitate abstinence in morphine 
dependent individuals. It appeared to have strong analgesic actions and low 
dependence producing properties. However, its short duration of action and 
numerous side effects including dysphoria, hallucination, unsteadiness, and 
feelings of drunkiness made it undesirable^’ 
112 113 
In the mid 1960's, Martin et al. ’ began investigating the use of 
another mixed agonist/antagonist-cyclazocine. This drug also precipitated 
abstinence symptoms. However, it had a longer duration of action than 
nalorphine lasting up to 12 hours with a peak at 2-3 hours, and was 10-20 times 
more potent than nalorphine. Tolerance developed to its agonist actions but not 
to its antagonist properties. Furthermore, it prevented or diminished both the 
euphoric and dependence producing properties of morphine. Side effects were 
similar to those of nalorphine with sedation, ataxia, hallucinations, etc. Since 
tolerance developed to these symptoms, cyclazocine was preferred over 
nalorphine by patients. Finally, a definite but mild abstinence syndrome was 
observed when cyclazocine was abruptly stopped but did not lead to drug 
seeking behavior. 
78 
3affe conducted the initial clinical trials with cyclazocine finding that 
it would be taken voluntarily by a group of well motivated addicts. Subjects 
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were slowly inducted onto the drug 48-72 hours after methadone withdrawal 
having proven successful detoxification with a negative nalorphine test. Jaffe 
found that his patients liked the drug claiming that they had more energy and a 
decreased desire for narcotics. When patients tested the drug with heroin some 
were very relieved to discover that it did indeed minimize or completely block 
heroin's euphorigenic effects. Jaffe even suggested the use of cyclazocine for 
extended periods of time since maintenance therapy had actually been 
requested by some patients. 
84 85 
Kleber ’ conducted a long term outpatient trial with cyclazocine. He 
found that the side effects experienced during induction were a problem but 
that naloxone could control these symptoms. The combination resulted in an 
eighty percent induction rate. This trial was conducted in a low intervention 
treatment setting in which subjects attended clinic daily for their cyclazocine 
doses and had scheduled group therapy sessions two nights a week. 
The search for antagonists with less agonist properties and fewer 
39 
objectionable side effects led to the development of naloxone. Foldes 
specifically investigated the respiratory and circulatory effects of naloxone as 
compared to nalorphine and oxymorphine. He found that naloxone itself had no 
respiratory depressant effects and was more effective than nalorphine in 
antagonizing respiratory depression caused by oxymorphine. However, naloxone 
did cause pulse rate and systolic blood pressure depression similar to nalorphine 
and was no more effective at preventing oxymorphine induced systolic blood 
pressure drops than nalorphine. 
81 
More extensive studies by Jasinski and Martin compared naloxone to 
nalorphine, cyclazocine, and placebo. Naloxone had essentially no agonist 
activity failing to elicit miosis or subjective changes such as drunkiness, 




hallucinations, etc. The only characteristic which differentiated naloxone 
subjects from the placebo control group was more sleepiness. Naloxone 
effectively antagonized morphine without the development of tolerance to its 
antagonist actions. It proved to be seven times more potent than nalorphine in 
precipitating abstinence and differed from the mixed agonist/antagonist agents 
by failing to show evidence of an abstinence syndrome after the cessation of 
chronic use. 
Although Jasinski's work suggested that naloxone was preferable to 
cyclazocine or nalorphine as an antagonist agent, larger doses were required for 
24 hour blockade making widespread use of this expensive compound for 
204 
maintenance impractical. A study by Zaks demonstrated that up to 2.4 gm 
of orally administered naloxone was necessary to ensure 24 hour blockage to a 
25 mg dose of heroin while 3 gm was necessary if a heroin challenge was 
increased to 50 mg. No untoward side effects were noted from these high doses 
of naloxone and Zaks expressed the need for a longer acting and/or slow release 
preparation. 
Long term outpatient naloxone therapy was studied by Kleber and 
Pierson.84,135 the study was conducted over three and one half years with 176 
young heroin abusers who were treated in a high intervention setting. This 
consisted of "confrontation style" therapy with eight hour sessions five days per 
week. Naloxone was used for the first six months of the year long program at 
doses of 800 mg per day. The drug was well tolerated and thirty-nine percent 
of the participants remained opiate free for one to three years after treatment. 
The 800 mg naloxone dose was less than would be required for 24 hour receptor 
blockade. However, in this study the eight hours per day of supervision 
eliminated the need for higher doses. 
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Naltrexone proved to be one answer to the dosage problem. Studies by 
Gritz,5? Martin,117 Resnick, ^ and Brahen15 showed that naltrexone's 
antagonist activity was 17 times more potent than nalorphine and twice as 
potent as naloxone. Furthermore, naltrexone was 2.5 times more potent than 
naloxone in its ability to precipitate abstinence having a longer period of 
actions with a half life which was twice as long as that of naloxone. Oral doses 
of naltrexone in the 30-50 mg range provided 24 hour blockade to heroin 
challenges which required up to 3 gm of naloxone. Naltrexone's ability to 
precipitate morphine abstinence symptoms began within 15-30 minutes and 
decreased over the next hour. Furthermore, like naloxone, abrupt cessation 
after chronic use did not produce an abstinence syndrome. 
148 
During induction at doses of 20-50 mg, Resnick found that patients 
complained of nervousness, irritability, difficulty falling asleep, abdominal pain, 
nausea and vomiting. However, Martin117 only observed subjective changes in 
57 
one indivdual who was given an initial dose of 70 mg subcutaneously. Gritz 
believed that the abdominal complaints may indeed have been from naltrexone 
since his subjects who had been abstinent for 2.5 months experienced similar 
symptoms. In any case, these complaints subsided with dosage stabilization 
indicating that they were only transitory. In a study comparing induction on 
naltrexone and cyclazocine, Brahen1^ found that naltrexone's gastrointestinal 
side effects were well tolerated enabling participants to achieve maintenance 
doses while cyclazocine side effects were too numerous and severe resulting in 
a high drop out rate. 
Changes observed during chronic naltrexone use included a fall in body 
57 
temperature and an increase in diastolic blood pressure. In all studies, no 
148 
toxic effects on EKG, blood or urinalysis were noted. As per Resnick, 50 mg 
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of naltrexone is sufficient for 24 hour blockade of a 25 mg heroin test dose 
while 48 hour blockade is accomplished with more than 120 mg and 72 hour 
blockade with 200 mg. 
Long term clinical trials have been conducted to assess naltrexone 
maintenance therapy. Altman, Meyer, Mirin et al.^ found that naltrexone 
maintained addicts did not test its antagonist properties. Therefore, extinction 
could not occur and based on Wikler's theory and these individuals would be 
susceptible to opiate craving when naltrexone was discontinued. Since their 
subjects knew that the antagonist was expected to prevent opiate agonist 
actions, they suggested that the anticipation of successful antagonism might 
have led to the lack of opiate use. Furthermore, they found that craving levels 
corresponded to the perceived availability of heroin. The highest craving levels 
122 84 
were recorded when heroin was known to be most available. Kleber, on 
the other hand, has suggested that extinction might be occurring even in the 
absence of actual drug use. He claimed that abstinence in an environment 
which was previously associated with drug use could extinguish the drug-seeking 
response. 
In another study, Sideroff*^ followed patients in a nine month outpatient 
naltrexone program. He found a high drop out rate at one month or less with 
the rest of the group staying for more than three months. This initial high 
attrition rate appeared to be due to unacceptable opiate craving leading him to 
postulate that 3-5 weeks of naltrexone is necessary to achieve a satisfactory 
reduction in craving. Unlike the Altman, Meyer, Mirin study, his patients did 
test the naltrexone blockade and found a reduced level of craving afterwards. 
However, the maximum number of trials for any individual however was two 
which failed to demonstrate the expected increase frequency of responses prior 
. 
: < . .• 
■ i U 
52 
to extinction. Patients who left the program later than one month did not 
complain about craving. Instead they felt uncomfortable in the nonopiate 
environment or believed that they were ready to be completely free of outside 
support systems. 
In summary, these studies showed that naltrexone may be useful for a 
small group of well-motivated opiate addicts enabling them to become opiate 
free without fear of readdiction. Even if extinction is not playing a role 
antagonists might aid in the protracted abstinence syndrome. As previously 
discussed, chronic antagonist treatment causes an increase in the number of 
opiate receptor binding sites. As such, it had been suggested that this receptor 
enhancement would make patients more sensitive to opiates and decrease the 
need for both exogenous and endogenous opiates the later of which may be 
depressed in chronic opiate addiction and contribute to the protracted 
abstinence syndrome. 
USE OF OPIATE ANTAGONISTS FOR DETOXIFICATION 
149 
Resnick et al. described a clinical trial in which naloxone precipitated 
withdrawal was utilized as a method for rapid opiate detoxification. He 
suggested that a shorter period of detoxification should enable patients to be 
placed on protective naltrexone therapy sooner and eliminate the vulnerable 
period of 5-10 opiate free days prior to naltrexone induction. Thirty-three 
subjects with methadone maintenance doses of 5-20 mg were premedicated with 
10-15 mg of diazepam and 0.4 mg of atropine. This was followed by repeated 
intramuscular injections of naloxone over a one to two day period until 
precipitated abstinence was eliminated. This procedure was followed by a 1.2 
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mg naloxone test dose on the second or third day respectively with subsequent 
induction onto naltrexone therapy. Some of the individuals in the two day 
detoxification group did have a positive naloxone test and could not be started 
on naltrexone on that day. Resnick postulated that opiates remaining in the 
body had reoccupied receptors overnight and that naloxone displacement 
initiated withdrawal symptoms. He found this procedure to be safe with 
relatively small changes in vital signs. Most patients in this study preferred a 
more intense but briefer detoxification to gradual methadone withdrawal. 
There has not been much literature on this method of detoxification and a 
single trial by Riordan (personal communication) proved to be unsuccessful. 
The patient terminated the trial because of unbearable withdrawal symptoms. 
As such, Riordan and Kleber^^ attempted an initial clinical trial using 
naloxone and clonidine in combination. Their study included three heroin 
abusers with an average habit of 60 mg per day and methadone patient with a 
25 mg per day dosage. Opiate was stopped on day one and clonidine was 
administered in three doses. On day two, intramuscular naloxone doses every 
two hours starting at 0.2mg and increasing to 0A mg were added to the three 
times per day clonidine regimen as tolerated. This was continued on day three 
increasing the naloxone dose to 0.8 mg every two hours. On day 4, a naloxone 
test dose was administered and if no reaction occurred, naltrexone induction 
was begun. All of the patients were successfully detoxified and had negative 
naloxone tests on day i+. Withdrawal ratings were highest on day two with 
scores in the five to nine range after the first two naloxone doses. However, 
scores for day three showed only one or two symptoms. 
Following this initial trial, Riordan and Kiebar suggested that naltrexone 
might be even better than naloxone in this detoxification technique. The 
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purpose of the current study is to evaluate the effectiveness of a 
clonidine/naltrexone combination in producing a rapid well tolerated 
detoxification. The use of naltrexone would permit oral administration and 
prevent the necessity of frequent intramuscular or intravenous injections. 
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MATERIALS AND METHODS 
This study was divided into two parts comprising a total of five male and 
three female volunteers who were members in good standing at methadone 
maintenance programs in Connecticut. Participants were prescreened by both 
their counselors at their respective methadone clinic and the responsible 
physician at the Connecticut Mental Health Center in New Haven, Connecticut 
to determine that detoxification was appropriate. On admission to the locked 
inpatient ward at Connecticut Mental Health Center, patients were given a 
standard admission interview with specific emphasis on previous drug abuse 
history. In addition, they were screened for major illnesses with a thorough 
physical examination and laboratory work consisting of a CBC with differential, 
erythrocyte sedimentation rate, electrolytes, blood urea nitrogen, creatinine, 
glucose, liver function tests, thyroid function tests, VDRL, urinalysis, 
electrocardiogram, hepatitis titre and where appropriate a pregnancy test. If 
the subjects had not taken their daily methadone dose this was administered. 
Baseline measurements were made of vital signs - recording pulse and blood 
pressure in both the prone and sitting positions. Baseline withdrawal 
symptomatology was determined by rating for the presence or absence, not 
degree, of 18 items which included the subjective symptoms: craving, anxiety, 
goose-flesh, hot and cold flashes, aching of muscles and bones, anorexia, 
insomnia, restlessness, nausea, vomiting, diarrhea, and spontaneous orgasm as 
well as the objective items: yawning, perspiration, lacrimation, rhinnorhea, yen 
sleep, and tremors. Analogue scales were also completed rating energy, 
nervousness, irritability, feelings of being uninvolved, and unpleasantness on a 







discontinue the study at any time. Visitors were not permitted prior to the 
completion of detoxification but they had unlimited access to the public ward 
telephone. Subjects were told that they would be undergoing a rapid 
detoxification using a combination of either methadone, clonidine or placebo 
and either antagonist or placebo. They would be blind to the types of drugs 
administered but were guaranteed to be detoxified if they completed the study. 
Finally, all were given the option of participating in the naltrexone aftercare 
program. 
PART I 
Two men and one woman were detoxified on the clonidine/naloxone 
protocol to demonstrate the efficiacy and safety of this combination as well as 
determine dosing schedules. The average age of this group was 32+ 2.5 with an 
average of 9+ 4.6 years of opiate addiction and 5.3+ 3.1 years on methadone 
maintenance. As a group they had 4.7+ 4.6 (range 2-10) previous detoxification 
attempts and had been maintained on an average of 20+ 0 mg of methadone 
over the three months prior to admission. On day one, their usual methadone 
maintenance dose was administered. On day two, the methadone was abruptly 
stopped and clonidine was administered orally in an orange flavored solution 
under double blind conditions. Only the physician overseeing the study was 
aware of dosing schedules. The initial 9AM clonidine dose was 5 pg/kg. 
Subsequent doses at 3PM and 9PM were individually adjusted on the basis of 
vital signs and withdrawal symptoms. Withdrawal ratings and analogue scales 
were completed prior to each dose. Clonidine doses were held for a pulse rate 
less than 50 or a blood pressure less than 90/60 and the responsible 
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physician was notified. On day three clonidine was administered every four 
hours. Two hours after the morning clonidine dose, intravenous naloxone was 
administered in a single blind fashion. If a test dose of 0.1 mg did not cause 
severe withdrawal symptoms, it was repeated in one hour. Doses were 
increased by 0.1 mg every hour as tolerated to maximum of 0.3 mg per dose. 
Withdrawal ratings and vital signs were measured prior to each naloxone dose 
and naloxone was held with notification of the responsible physician if symptom 
ratings exceeded five. Day four continued in the same manner with naloxone 
doses being increased to a maximum of 0.7 mg per dose. On day five, a 
naloxone challenge of 1.2 mg IM was administered. At this point, the three 
subjects were treated differently. One had his clonidine abruptly terminated, 
another had a rapid dose reduction with a four day taper, and the third had a 
slow three day taper. Two out of the three subjects expressed an interest in 
naltrexone maintenance. Induction onto the drug in a nonblind fashion with 
doses of 5-10 mg every three hours to a maximum of 40 mg on Day 5 was 
possible if the naloxone challenge test was negative. A single 50 mg naltrexone 
dose would then be administered starting on day six. Naltrexone was 
administered orally in fruit juice. 
PART II 
Three men and two women were studied on a clonidine/naitrexone 
protocol. The mean age of the group was 28.4+ 4.0 with an average of 8.6+ 3.1 
years of opiate addiction and 4.4+ 3.2 years (range 2-10) on methadone 
maintenance. They had undergone an average of 2.4+ 0.9 previous 
detoxification attempts and were admitted on an average three month 
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methadone maintenance dose of 30.6+ 17.4 mg (range 10-58). Days one and two 
were identical to Part I. On day three they were given clonidine in a double 
blind fashion and naltrexone in a single blind fashion as described in Part I. 
Clonidine and naltrexone were administered together at four hour intervals and 
withdrawal ratings and vital signs were measured prior to each dose. 
Naltrexone was begun at 1 mg and increased to a maximum of 2 mg per dose as 
tolerated. (The first subject was actually started at 2 mg but this was 
abandoned because of the difficulties he encountered - see results). Day four 
was conducted in the same manner increasing naltrexone to a maximum of 8 mg 
per dose. On day five, naltrexone was administered at 10 mg per dose until 
approximately a 40 mg maximum for the day had been reached. In addition, a 
slow clonidine taper was begun with the aim of tapering the dose by 
approximately fifty percent per day over a 2-4 day period as tolerated. On day 
six, naltrexone was given as a single 50 mg dose and on day seven most patients 
were discnarged after a single dose of clonidine and naltrexone. No limit was 
set on the length of stay and subjects were welcome to extend their stay beyond 
a week. Flurazepam and chloral hydrate were used as needed for sleep. 
Note: Clonidine was suppled as CATAPRES*^ 
O 
Naloxone was supplied as NARCAN 
Naltrexone was supplied by the National Institute on Drug Abuse 
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PART I - CASE REPORTS 
SUBJECT 1 was a 34 year old black male who had a four year history of 
opiate addiction, a two year history of methadone maintenance, two previous 
detoxification attempts, and a daily methadone maintenance dose of 20 mg for 
the three months prior to admission. 
DAY h On the day of admission he exhibited no withdrawal 
symptoms. 
DAY 2: Clonidine was safely started at a dose of 0.4 mg three 
times per day. There was no evidence of severe postural hypotension, 
bradycardia or the emergence of withdrawal symptoms. 
DAY 3: He was easily inducted onto naloxone reaching a dose of 
0.2 mg per hour by dose four and 0.3 mg per hour by dose eight. Clonidine 
was increased to 0.45 mg per dose and was effective in minimizing his 
withdrawal symptoms which averaged 0.9 per rating (range 0-4). 
DAY 4: This day proceeded smoothly as well with the subject 
reaching a naloxone dose of 0.7 mg per hour by dose seven. Clonidine was 
successfully decreased to 0.4 mg per dose by mid-afternoon and the 
average number of withdrawal symptoms was lower than on the previous 
day at 0.6 symptoms per rating. 
DAY 5: Clonidine was stopped after an initial 9 AM dose of 0.3 
mg. He successfully passed a 1.2 mg naloxone challenge test and was 
begun on naltrexone induction at 10 mg four times per day. By 
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the evening, however, his withdrawal symptoms had recurred increasing 
from a level of one per rating to six per rating. The average number of 
symptoms for this day was three per rating. 
DAY 6: The increase in withdrawal symptoms proved to be only 
transient. He began a downward trend again with an average of two 
symptoms per rating. In addition, he was able to take a single 50 mg 
naltrexone dose without a reemergence of severe abstinence symtoms. 
DAY 7: He was discharged after receiving a 50 mg dose of 
naltrexone. (See TABLE la, TABLE lb and FIGURE 1) 
SUBJECT 2 was a 32 year old white male who had a three year history of 
opiate addiction, an eight year history of methadone maintenance, two previous 
detoxification attempts, and a methadone maintenance dose of 20 mg for the 
three months prior to admission. 
DAY _1: He exhibited two withdrawal symptoms on admission. 
DAY 2: Clonidine was begun at 0.3 mg three times per day. This 
appeared to be adequate coverage since he only had 1.7 symptoms on 
average per rating. Although his blood pressure fell from a baseline of 
122/90 to 80/50, he did not experience any syncopal episodes and 
maintained his vital signs at an average blood pressure of 97/62 and a 
pulse of 81. 
DAY 3: He was inducted onto naloxone reaching a dose of 0.2 mg 
per dose by dose three and 0.3 mg per dose by dose seven. Clonidine was 
increased to 0.35 mg per dose which successfully minimized his 
withdrawal symptoms which were on average actually less than on 
admission at 0.7 symptoms per rating (range 0-3). Vital signs were not 
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severely affected even at this higher dose of clonidine. On average his 
blood pressure read 110/73 with a pulse of 71. 
DAY 4: He reached 0.4 mg of naloxone by dose three, 0.5 mg by 
dose five, 0.6 mg by dose ten, and 0.7 mg by dose thirteen. Clonidine was 
again increased on this day to treat his withdrawal symptoms which had 
increased to an average of 1.8 symptoms per rating. As on the previous 
day, vital signs remained stable. 
DAY 5; He successfully passed a 1.2 mg naloxone challenge but 
requested not to be begun on naltrexone induction. In addition, the 
clonidine dosage was sharply reduced from a total of 2.4 mg (27 yg/kg) on 
the previous day to 0.4 mg (4 yk/kg). It is important to note that this was 
a clonidine taper not termination as with Subject 1. 
DAY 6: On this day he experienced more withdrawal symptoms 
averaging 4.3 per rating (range 3-5) while on a clonidine dose of 0.5 mg 
per day. 
DAY 7: An increase in clonidine to 0.7 mg per day was 
accompanied by a downward trend in his average symptom rating to 3.7. 
DAY 8: The downward trend in symptoms continued and he was 
discharged after final clonidine dose of 0.2 mg and a rating of two on the 
withdrawal scale. (See TABLE la, TABLE lb, FIGURE 2) 
SUBJECT 3 was a 29 year old white female with a ten year history of 
opiate addiction, a six year history of methadone maintenance, ten previous 
detoxification attempts, and a daily methadone dose of 20 mg over the three 
months prior to admission. 
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DAY k She was admitted with a withdrawal symptom rating of 
one. 
DAY 2: Clonidine was ordered at 0.25 mg three times per day 
and was supplemented with an extra dose of 0.1 mg to cover the increase 
in withdrawal symptoms which averaged 2.7 per rating. Vital signs 
remained stable throughout his day without significant drops in blood 
pressure or pulse changes. 
DAY 3: She was slowly inducted onto naloxone and reached 0.2 
mg by dose six but did not achieve a dose of 0.3 mg. She appeared to be 
experiencing more withdrawal symptoms than previous subjects and 
required a few naloxone doses to be held for symptom ratings of five 
despite increases in clonidine to 0.4 mg per dose. The average number of 
symptoms per rating for that day was 3 (range 1-5). The clonidine doses 
were well tolerated with stable vital signs at an average blood pressure of 
100/66 and a pulse of 65. 
DAY 4: She was started on 0.3 mg of naloxone reaching 0A mg 
by dose three, 0.5 mg by dose five, and 0.6 mg by dose nine. As during the 
previous day, the symptom ratings reached a high level. One naloxone 
dose was cut in half for a symptom rating of seven. However, the usual 
naloxone dosing regimen was resumed and well tolerated at the next time 
point. Occasional doses of clonidine in the range of 0.5 mg per dose were 
required to keep the average symptoms rating low at 3.9 (range 3-7). 
DAY 5: A clonidine taper of approximately fifty percent per day 
was begun. The final total dose of clonidine on this day was 0.8 mg (13 
yk/kg) as compared to 2.65 (44 yk/kg) on the previous day. In addition, 
naltrexone induction was successfully accomplished without a 
reemergence of withdrawal symptoms. 
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DAY 6: The clonidine taper was continued and she was given a 
single 50 mg dose of naltrexone. 
DAY 7: This day proceeded as described for day six except that 
the clonidine was stopped after a final dose of 0.1 mg. 
DAY 8: She continued to show a downward trend in the symptom 
ratings despite the daily 50 mg naltrexone doses and the absence of 
clonidine therapy. Her average symptom rating for this day was 0.5. 
Unlike the other subjects she remained for eleven days and actually 
started on a 150 mg maintenance dose of naltrexone. (See TABLE la, 
TABLE lb, FIGURE 3) 
PART II 
SUBJECT 4 was a 23 year old white male who had a five year history of 
opiate addiction, a three year history of methadone maintenance, two previous 
detoxification attempts, and a methadone maintenance dose of 30 mg for the 
three months prior to admission. 
DAY h He was admitted without any withdrawal symptoms. 
DAY 2: Clonidine was successfully administered without 
evidence of significant blood pressure or pulse changes. He did 
experience some withdrawal symptoms but these were well managed with 
an extra dose of clonidine. 
DAY 3: Unlike the rest of Group II, he was started on a 2 mg 
dose of naltrexone. This produced a marked increase in his withdrawal 
symptoms and one naltrexone dose had to be held while the clonidine was 
increased to 0.5 mg per dose during the course of the day. 
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DAY 4: He was able to achieve a dose of 8 mg of natrexone by 
dose three without an exacerbation of symptoms. In fact, his average 
withdrawal rating score decreased from 6.5 on day three to 3.7 on this 
day. Clonidine doses were maintained in the 0.4 - 0.5 range without 
severe side effects. 
DAY 5: A slow clonidine taper was begun while naltrexone doses 
were increased to 10 mg four times per day. 
DAY 6: A single 50 mg dose of naltrexone was well tolerated 
while the three day clonidine taper continued. 
DAY 7: The last dose of 0.2 mg of clonidine was administered 
and he was discharged without having shown evidence of a reemergence of 
withdrawal symptoms or evidence of clonidine withdrawal 
symptomatology. (See TABLE Ila, TABLE lib, FIGURE 4) 
SUBJECTS 5 and 7 will be discussed together because of their similar 
hospital courses. SUBJECT 5 was a 25 year old Puerto Rican male with an 
eleven year history of opiate addiction, a two year history of methadone 
maintenance, three previous detoxification attempts, and a stable methadone 
maintenance dose of 25 mg per day for at least three months prior to admission. 
SUBJECT 7 was a 34 year old white female who had a twelve year history of 
opiate aadiciton, a ten year history of methadone maintenance, one previous 
detoxification attempt, and an average methadone maintenance dose of 10 mg 
per day for much greater than three months prior to admission. 
DAY 1: SUBJECT 5 was admitted without evidence of any 
withdrawal symptoms while SUBJECT 7 was rated as having two 
symptoms. 
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DAY 2: During cJonidine therapy, both subjects experienced a 
slight increase in their withdrawal symptoms as well as blood pressure 
drops below 90/60. However, they did not have any syncopal episodes and 
only experienced lightheadedness on standing. SUBJECT 5 was managed 
by reducing one of his three clonidine doses by 0.05 mg. SUBJECT 7's 
dosage was not manipulated in the interest of covering her withdrawal 
symptoms. This did not appear to be dangerous from a cardiovascular 
standpoint. 
DAY 3: Both subjects were successfully started on naltrexone at 
1 mg and achieved a level of 2 mg by the third dose. Increases in 
withdrawal symptom ratings were treated by increasing the clonidine dose 
to 0.5 mg in SUBJECT 5. This could not be done for SUBJECT 7 because 
of borderline blood pressure readings on 0.3 mg of clonidine. When 
expressed in micrograms per kilogram, SUBJECT 7's clonidine dose was 
approximately half that for the others in Group II. However, it was not 
necessary to hold naltrexone doses for either subject since withdrawal 
symptom ratings were relatively low at 2.3 (range 1-4) for SUBJECT 5 and 
moderate at 4.6 (range 3-5) for SUBJECT 7 despite her lower levels of 
clonidine. 
DAY 4: Both individuals had achieved an 8 mg dose of naltrexone 
by dose four. Neither required manipulation of their clonidine doses and 
both showed evidence of a downward trend in the severity of their 
withdrawal symptoms. 
DAY 5: A clonidine taper was begun and the 10 mg four times 
per day naltrexone regimen was initiated. 
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DAY 6: A single 50 mg naltrexone dose was administered while 
the clonidine taper continued for both subjects. SUBJECT 5 did show a 
slight increase in symptoms on this day. This may have been due to the 
fact that he had a more severe clonidine taper on day five as compared 
to SUBJECT 7. SUBJECT 7 left on the evening of day six without having 
shown a reemergence of withdrawal symptoms. 
DAY 7: The increase in withdrawal symptoms for SUBJECT 5 
proved to be transient and the downward trend continued despite the 
clonidine taper. His last dose of 0.2 mg was given and he was discharged. 
(See TABLE Ha, TABLE lib, FIGURES 5,7) 
SUBJECT 6 was a 30 year old white female who had a nine year history of 
opiate addiction, a three year history of methadone maintenance, and three 
previous detoxification attempts. She was admitted on a dose of 35 mg of 
methadone but unbeknownst to us had only been on that dose for a week prior to 
admission. Her highest dose in the three preceding months had been 75 mg with 
an average dose of 58 mg. 
DAY 1_: She was admitted with three withdrawal symptoms. 
DAY 2: She tolerated the usual clonidine regimen well. In fact, 
her withdrawal symptoms actually decreased to an average of two per 
rating. 
DAY 3: She was successfully begun on 1 mg of naltrexone and 
increased to 2 mg by the second dose. Her withdrawal symptoms were 
kept at an average of 3.3 (range 3-4) with up to 0.5 mg of clonidine. 
DAY 4: Clonidine was maintained at 0.45 mg per dose and she 
reached naltrexone dose of 8 mg by the fourth dose. Her average 
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withdrawal symptom rating decreased to 2.6 and there was no evidence of 
adverse effects from clonidine. 
DAY 5: A 10 mg per dose naltrexone regimen was begun and a 50 
percent clonidine taper was started while the average withdrawal 
symptomatology remained at 2.6 per rating. In addition, on this day she 
began complaining about severe anxiety and the feeling that her "insides 
were going to explode". 
DAY 6: The anxiety continued through day 6 despite seven 10 mg 
doses of diazepam over the preceding 36 hours. When questioned about 
her thoughts on the matter, it became apparent that she was afraid of 
being detoxified from methadone and was not sure that she could make it 
without the drug. In addition, she had multiple family problems which 
were mounting and not resolvable in the near future. Despite these 
complications, she was able to take a single 50 mg dose of naltrexone 
without experiencing a marked rise in her withdrawal symptoms. 
DAY 7: Her anxiety level reached a peak on this day and she was 
given 50 mg of thioridizine which produced a remarkable reduction in her 
anxiety. At this time the anxiety appeared to be due to outside pressures 
as opposed to a manifestation of withdrawal. However, her distraught 
state probably contributed to the upward trend in her withdrawal 
symptoms on this day. 
DAY 8: She received her last dose of clonidine. 
DAY 9: She was observed off clonidine while continuing with 
daily 50 mg naltrexone doses and failed to show a reemergence of 
withdrawal symptoms. It is of interest that on discharge she was the only 
member of Group II who elected to try naltrexone maintenance. (See 
TABLE Ila, TABLE lib, FIGURE 6) 
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SUBJECT 8 was a 27 year old white male who had a six year history of 
opiate addiciton, four year history of methadone maintenance, and three 
previous detoxification attempts. He also had been detoxifying from higher 
methadone doses but he had been on a stable dose of 25 mg for three weeks 
prior to admission. His average methadone dose over the three months prior to 
admission was 30 mg. 
PAY 1: On admission he had no withdrawal symptoms. 
DAY 2: This day went well on the usual clonidine regimen. 
DAY 3: Naltrexone was begun at 1 mg. However, he was unable 
to advance to 2 mg because of severe anxiety and tension. These were 
felt to be withdrawal symptoms since he reported similar reactions during 
previous detoxification attempts. Furthermore, these symptoms were not 
present prior to the onset of naltrexone therapy. His average symptom 
rating remained at 4.2 (range 1-6) despite doses of clonidine of up to 0.5 
mg. When the anxiety was not relieved by 10 mg of diazepam and 2 gm of 
chloral hydrate, 100 mg of thioridizine was tried. This proved to be 
beneficial and repetition was not necessary. 
DAY 4: He was able to advance to 7 mg of naltrexone by dose 
four while on 0.6 mg of clonidine per dose. This seemingly high dose of 
clonidine was well tolerated and he maintained an average blood pressure 
of 99/70 with a pulse of 74. This is not surprising when the dose is 
evaluated in terms of micrograms per kilogram. His total clonidine dose 
on that day was actually not much greater than the other members of the 
group. In addition, his symptoms decreased ot an average of 1.2 per 
rating (range 0-3). 
C 1 
'*'* r' ' • 
si t f _ *. ^'n l » • > 
v l. - » V '✓«: i i. / 
i i. j 4 v * ✓ - U. Si.'* . > / Vj 
-wH 
r .•. * j .»«_•> . » • /. V/ 
/V1 • ^ J (i t l • . I 
t j • -• i j„ r J . J . • / * • J j •* • Ai »i;|i : d toil i 
r; » J no 
69 
DAY 5: As with the other members of Group II, he was able to 
reach the 10 mg Q.I.D. naltrexone dosage regimen on day five as well as 
begin the clonidine taper. 
DAY 6: He tolerated the 50 mg naltrexone dose and was able to 
continue the clonidine taper despite a small increase in withdrawal 
symptoms for 1.2 on day four to 2.7 on day six. 
DAY 7: The downward trend on symptoms resumed and he was 
discharged after a final clonidine dose of 0.1 mg. (See TABLE Ila, TABLE 
lib, FIGURE 8) 
GROUP II - COMBINED DATA 
On the whole, Group II tolerated this protocol very well. Although 
lightheadedness on standing was experienced by most subjects, there were no 
synocopal episodes and all marked drops in blood pressure could be handled 
satisfactorily by individual dose manipulations. Average sitting blood pressure 
and pulse readings for the group are charted in Table IV and graphed in Figure 
10. 
The group showed a peak clonidine dose on DAY 3 of 2.9+ 0.68 mg (44+ 9.2 
pg/kg) and were able to complete a three to four day clonidine taper without 
significant reemergence of withdrawal symptoms or evidence of a clonidine 
withdrawal syndrome (Table III). Withdrawal symptoms generally appeared 
within 45 minutes of naltrexone administration and abated over the next two 
hours. 
A peak in withdrawal symptoms was seen on DAY 3. This was the time at 
which naltrexone therapy was initiated. After this day, there was a downward 
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trend in the average number of withdrawal symptoms with a plateau of 
approximately two symptoms per rating between DAYS 5 and 7 (see Figure 9). 
The most common symptoms were insomnia, restlessness, muscle and bone 
aching, anxiety, craving, hot and cold flashes, anorexia, gooseflesh, diarrhea 
and yawning. A few subjects experienced tremors, yen sleep, rhinnorhea, 
lacrimation and nausea. No one reported vomiting, spontaneous orgasm or 
perspiration. Most of these symptoms had abated by DAY 6 and on DAY 7 the 
only symptoms reported were anxiety, bone and muscle aching, insomnia, 
restlessness, and rhinorrhea. Of these only insomnia and bone and muscle 
aching were reported more than 50% of the time. (See Table V). 
The means of Group II's analogue scales show that energy reached a low 
during DAYS 3 and 4 and returned to baseline by the end of the study. Most 
appeared to be nervous on DAY 1_ but gave lower ratings as the study progressed 
and as they became more comfortable with the staff and the environment. 
Scales of irritability, uninvolved and unpleasantness increased over the days of 
maximal withdrawal symptoms and decreased toward baseline at the end of the 
study. (Figures 11-15). 
Reasons for desiring detoxification at this time included feelings of being 
well established in a job and family situations; wishing to make a break from 
the drug environment which included methadone maintenance clinics; and 
pressure from family members. All subjects reported satisfaction with this 
method of detoxification. Many related that their symptoms were less severe 
than during previous detoxification attempts. Although one subject felt that his 
symptoms on DAY 3 were comparable to previous experiences, the fact that 
they only lasted for one to two days made this method more desirable for him. 
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Only one subject wished to participate in the naltrexone program. The 
other subjects felt that they needed to make a complete break from any 
association with the drug culture and were confident of their ability to do so 




Many theories have been invoked to explain the events which occur during 
opiate dependence, withdrawal and relapse. They have included possible 
changes in opiate receptor number and/or affinity; changes in postsynaptic 3 
receptor number, reduced levels of endogenous opiate peptides secondary to 
either decreased synthesis or increased enzymatic degradation; and 
hyperactivity of central noradrenergic neurons. Specific attention to this last 
hypothesis arose with the discovery of a relationship between the locus 
coeruleus and cortical norepinephrine turnover.92,93 lc firing was observed to 
2 
increase during naloxone induced withdrawal in morphine dependent rats and 
norepinephrine turnover was increased in LC innervated brain regions during 
27 102 
naloxone precipitated withdrawal. ’ The LC could be depressed by 
morphine, met-enkephalin, and clonidine - an a 2 adrenergic 
94 202 99 11 2 
agonist. ’ ’ ’ ’ Furthermore, clonidine depressed the elevated levels of 
27 
norepinephrine turnover during withdrawal. Behavioral studies in nonhuman 
primates showed that similar behaviors could be induced by LC stimulation, 
piperoxane administration, human threats, and opiate 
43 140 141 144 145 
withdrawal ’ ’ ’ ’ while clonidine, morphine and met-enkephalin 
were able to depress the LC stimulation and piperoxane induced 
43 71 142 
behaviors. ’ ’ Finally, clonidine was observed to suppress the opiate 
38 
withdrawal syndrome in rats. 
These studies led to the hypothesis of a hyperadrenergic state during 
withdrawal centered in the LC which could be suppressed by the nonopiate drug 





repeated by several investigators.22,44,45,46,50,49,184,188,190 j-jowever> this 
method required 8-14 days and did not eliminate the vulnerable period of five to 
ten days after methadone is stopped before it is possible to initiate antagonist 
aftercare therapy. Prior to the clonidine studies, trials were conducted with 
naloxone in an attempt to find a more rapid method of detoxification which 
would shorten the lag period. Although this was reported to be successful, 
other investigators were not able to repeat the results. Recently, Riordan and 
Kleber^^ attempted to use clonidine and naloxone in combination. Their 
success with an initial trial prompted this study to confirm the efficacy and 
safety of the method, determine appropriate dosing schedules, and attempt 
substitution of the longer acting orally effective antagonist naltrexone in the 
place of naloxone. 
The results of PART I demonstrated that a safe rapid three day 
detoxification from methadone could be accomplished as previously described 
by Riordan and Kleber using a clonidine/naloxone combination. There were no 
severe changes in blood pressure or pulse which could not be controlled by 
minor individual clonidine dose manipulation. All subjects could begin induction 
onto naltrexone on the fourth day after methadone was abruptly stopped. 
Furthermore, 24 hour receptor coverage at a dose of 50 mg of naltrexone could 
be achieved by the fifth day. The various schedules used to taper clonidine 
demonstrated that a slow three to four day taper was necessary to prevent the 
reemergence of withdrawal symptoms. Using such a method also prevented the 
appearance of a clonidine withdrawal syndrome. Based on these results, it 
seems doubtful that naloxone detoxification accompanied only by prernedication 
with atropine and diazepam would be tolerated in a rapid detoxification as 
2 
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quickly in the naloxone induction protocol as compared to other subjects despite 
fairly high doses of clonidine. 
The results of PART II indicated that the same three day detoxification 
could be accomplished using the longer acting orally active opiate antagonist 
naltrexone in combination with clonidine. Therefore, the necessity of frequent 
intravenous or intramuscular injections both in this study and others 1^,150 
could be eliminated. Naltrexone's longer half life and greater potency in 
precipitating abstinence did not become a problem since a slow induction with 
one mg increments was possible and all the abstinence symptoms with the 
exception of anxiety in SUBJECT 8 could be controlled with clonidine. The 
importance of starting at one mg was illustrated in SUBJECT 4 wno 
experienced severe symptoms when begun at two mg and required a naltrexone 
dose to be held. The significance of the anxiety reaction in SUBJECT 8, which 
appeared to be related to precipitated abstinence and required the use of 
additional medication i.e. diazepam and thioridizine, cannot be evaluated 
without examining a larger population. As previously discussed, the anxiety in 
SUBJECT 6 did not appear to be part of the withdrawal syndrome and no other 
subjects in either the naloxone or naltrexone protocols had similar experiences. 
In any case, the single dose of thioridizine was effective in SUBJECT 8 and did 
not require repetition. He was able to continue on with the protocol as 
originally designed and complete it in the same amount of time as the rest of 
the group. 
As described in the clonidine/naloxone study and numerous inpatient and 
outpatient clonidine detoxification studies, there were no irreversible adverse 
effects from clonidine. Individualized dosing regimens proved to be effective in 
controlling both abstinence symptoms and vital sign stability. The necessity of 
.i (. ! . 
75 
such individual attention was well illustrated by the fact that SUBJECT 8 could 
tolerate 0.6 mg of clonidine per dose while SUBJECT 7 was unable to be 
increased above 0.3 mg on DAY 3 without compromising her cardiovascular 
status. 
All subjects experienced most of their abstinence symptoms during the 
first three days of detoxification, were able to begin on 10 mg per dose of 
naltrexone on the fifth day after methadone withdrawal, and tolerated a single 
50 mg dose of naltrexone on the sixth post methadone day. The slight increase 
in withdrawal symptom on DAYS 5 and 6 in some subjects was not severe. Both 
the clonidine taper and 50 mg naltrexone coverage could be continued. This 
increase may have represented a need for more clonidine on DAY 5 because of 
residual withdrawal symptoms. Unlike the heroin abstinence syndrome which 
peaks at two to three days and lasts for five to ten days, the methadone 
withdrawal syndrome peaks at three to four days and lasts for two to three 
weeks. This extended period of time could explain the upward trend in 
symptoms seen on days five and six in subjects who had a more rapid clonidine 
taper. A larger dose of clonidine with a slower taper probably would have 
prevented this from occurring. It is of note that subject four had the least 
amount of dosage reduction between days five and six and did not show this 
upward trend in withdrawal symptoms. If the patients had been detoxified from 
heroin, there might have been a more intense withdrawal syndrome initially. 
However, the increase in withdrawal symptoms during the clonidine taper 
probably would not have occurred since withdrawal would have been virtually 
complete at that time. 
There was no apparent correlation between the initial methadone 
maintenance dose and the severity of the withdrawal syndrome with this 
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method. All subjects regardless of being on low dose (10 mg) or higher dose (35 
mg) methadone therapy were able to ultimately complete the protocol as 
designed. Reactions appeared to be very individualized as SUBJECT 7 who was 
on 10 mg for many months actually experienced more withdrawal symptoms 
than SUBJECT 5 who was on 25 mg per day for several months. Previous 
49 
studies by Gold had demonstrated that clonidine detoxification could be 
applied to people with a 15 mg requirement as well as 75 mg. 
The types of symptoms experienced by the subjects were similar to those 
22 
described by Charney in a study on 22 patients in an inpatient detoxification 
trial on clonidine alone. As in that study, restlessness, anxiety, insomnia, and 
muscle and bone aching were very prominent. The presence of hot and cold 
flashes, craving, goose-flesh, anorexia, diarrhea, yawning, tremors, yen sleep, 
rhinnorhea, lacrimation, and nausea represented symptoms up to grade three 
and would be expected in the first few days of rapidly induced withdrawal with 
the antagonist. The symptoms remaining on DAYS 6 and 7, i.e., anxiety, 
insomnia, anorexia, and diarrhea could represent those observed during the first 
week of naltrexone therapy in other groups.However, they could also be 
withdrawal symptoms as previously discussed. 
Comparison of the clonidine/antagonist method of detoxification ot other 
methods reveals that this method which can be completed in approximately a 
week. This is considerably shorter than either methadone taper which required 
87 138 201 
a minimum of three weeks in most studies ’ ’ ; abrupt cessation of 
88 116 
methadone which is followed by at least three weeks of symptoms ’ ; or 
clonidine detoxification which requires 8-14 days after abrupt termination of 
methadone. Using data supplied by Charney (see Tables III and VI), on ten 
patients who were begun on clonidine and treated as needed to minimize 
• ,' I 
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withdrawal symptoms, it is apparent that although larger doses of clonidine 
were necessary on DAYS 3 and 4 for the group treated with naltrexone, the 
group as a whole was able to achieve lower mean clonidine doses sooner. In the 
clonidine/naltrexone study, the average dose on DAY 6 was 0.66 + 0.25 mg 
while the clonidine group required 1.1 + 0.3 mg. Furthermore on DAY 7, the 
clonidine naltrexone subjects had been tapered to 0.25 + 0.17 mg while the 
clonidine patients needed 1.0 + 0.3 mg to suppress their abstinence symptoms. 
Presumably, this represents the more rapid detoxification induced by antagonist 
therapy. The antagonist precipitates withdrawal by displacing opiates from 
their receptors. In doing so, it disrupts the equilibrium between the drug and 
its receptor. This might cause the methadone to be more rapidly metabolized 
than usual and create a shorter withdrawal syndrome. 
IMPLICATIONS 
From this pilot study, it appears that the clonidine/antagonist methods 
could be applied to the methadone patient population in the following manner. 
Methadone could be stopped at a level of approximately 20 mg and clonidine 
started on an outpatient basis. The next three days beginning with naltrexone 
induction would need to be conducted as an inpatient. This is necessary to 
monitor the hypotensive actions of clonidine and individual reactions to 
naltrexone induction. Furthermore, there would be benefit from the close one 
to one interactions available in the inpatient setting. Dishcarge would occur 
when the 50 mg dose of naltrexone was reached and the clonidine taper could be 
continued as an outpatient. In this way the patient would be on 24 hour 
naltrexone coverage and less susceptible to relapse in the community. 
-• . .1 
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Certainly this method of detoxification is not appropriate for all opiate 
addicts. Prospective participants should be well screened to determine reasons 
for detoxification as well as emotional and social stability. This point was well 
illustrated by the problems encountered with SUBJECT 6. The findings of 
29 186 
Cushman and Valliant should be kept in mind paying special attention to 
employment history and the degree of involvement in the drug-free 
environment. This method of detoxification would be especially appropriate for 
the client electing naltrexone aftercare since it would eliminate the five to ten 
day period post-detoxification previously required prior to the initation of 
antagonist therapy. 
FUTURE RESEARCH WITH POSSIBLE IMPROVEMENT 
More definite conclusions with statistical analysis could be drawn if a 
larger patient population was studied. Specific attention could be paid to the 
problem of anxiety as well as the effects of initial methadone maintenance 
dosage on outcome. The use of double blind methods for both medications and 
their administration in identical solutions would be preferable. The use of 
thioridizine, diazepam and flurazepam could certainly be criticized. In the 
cases of diazepam and flurazepam, these drugs have been shown to depress LC 
firing.^ In this respect, they would aad to the effects of clonidine. Insomnia 
and anxiety are problems which might affect successful outcome in this study. 
The use of these agents could just as well be viewed as an application of the 
same principles which led to the initial trials with clonidine. Certainly, one 
must keep in mind the fact that clonidine itself has been reported to cause 
insomnia and anxiety in individuals not undergoing withdrawal. Finally, it would 
be helpful to follow these individuals for at least a week and preferably longer 
j yin 3 . 
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FIGURE 5. AVERAGE NUMBER OF WITHDRAWAL SYMPTOMS VS. DAY 
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FIGURE 7. AVERAGE NUMBER OF WITHDRAWAL SYMPTOMS VS. DAY 





















FIGURE 9. AVERAGE NUMBER OF WITHDRAWAL SYMPTOMS VS. DAY-GROUP II 


















FIGURE 11. AVERAGE ENERGY RATING VS. DAY- GROUP II 
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TABLE V- AVERAGE FREQUENCY OF WITHDRAWAL SYMPTOMS- GROUP II 
DAY 
SYMPTOM ^ 1 
j 2 3 4 ' 5 6 ; 7 
CRAVING | 0 0 0.30 0.05 0.05 ; o j 0 
ANXIETY 0.20 0.07 0.61 0.16 0.28 0.27 0.13 
GOOSEFLESH 0.20 0.33 0.35 0.20 0.10 0.20 0 
HOT AMD COLD 
FLASHES I 0 0.07 0.42 0.22 0 0 0 
BONE, MUSCLE 
ACHING 0 0.13 0.52 0.47 0.31 0.73 0.50 
ANOREXIA 0.20 0.27 0.49 0.40 0.37 0.23 0 
INSOMNIA 0 0 0.60 0.60 0 0.20 0.60 
RESTLESSNESS 0 0.27 0.43 0.16 0.32 0 0.25 
NAUSEA 0 0 0.06 0 0 0 0 
VOMITING 0 0 0 0 0 0 0 
DIARRHEA 0 0 0.22 0.11 0.19 0.33 0 
SPONTANEOUS 
ORGASM 0 0 0 0 0 0 0 
YAWNING 0 0.33 0.17 0 0.20 0.33 0 
PERSPIRATION 0 0 0 0 0 0 0 
LACRIMATION 0 0.17 0.13 0.08 0.04 0 0 
RHINORRHEA 0.20 0,13 0.09 0.09 0.05 0 0.20 
YEN SLEEP 0 0.07 0.11 0.03 0.10 0 0 
TREMORS 0 0 0.02 0 0 0 0 
AVERAGE NUMBER 
OF RATINGS* 1 3 7 6 4 3 1 
*More ratings were obtained on various days because the status of the 
patient was changing more rapidly. 
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TABLE VI- AVERAGE CLONIDINE DOSE/DAY FOR TEN PATIENTS TREATED 
WITH CLONIDINE ALONE FOR METHADONE DETOXIFICATION * 
DAY DRUG DOSE MG/DAY 
1 METHADONE-23 MG 
CLONIDINE 
2 1.0 + 0.2 j 
3 1.0 + 0.2 
4 1.0 + 0.2 ; 
5 1.1 + 0.3 ! 
6 1.1 + 0.3 
7 1.0 +0.3 
8 1.0 + 0.3 
9 0.8 + 0.3 
10 0.6 + 0.3 
11 0.3 + 0.1 
12 0 ! 




FIGURES 1-8 - Average number of withdrawal symptoms vs. day for subjects 
1-8. 
FIGURE 9 - Average number of withdrawal symptoms vs. day for Group II. 
FIGURE 10 - Average sitting systolic blood pressure, diastolic blood pressure, 
and pulse vs. day for Group II. 
FIGURES 11-15 - Average analogue scale rating for the variables of energy, 
irritable, uninvolved, nervous, and unpleasant vs. day for Group II. The 
average number of ratings used to generate this data was one for DAY 1; 
three for DAY 2; seven for DAY 3; six for DAY 4; four for DAY 5; three for 
DAY 6; and one for DAY 7. There were more ratings on days in which there 
were frequent changes in the status of the patient. 
TABLE la - Doses of methadone, clonidine, naloxone, and naltrexone vs. day 
for subjects 1-3. Methadone is expressed in units of mg/day while clonidine, 
naloxone, and naltrexone are expressed in units of yg/kg/day. A dash in the 
box refers to the fact that the subject was not present on that day. In all 
cases the subject had been discharged. 
TABLE lb - Same as TABLE la except that it is doses of methadone, 
clonidine, and naltrexone for subjects 4-8. 
TABLE Ila - Doses of methadone, clonidine, naloxone, and naltrexone vs. day 
for subjects 1-3. All drug doses are expressed in units of mg/day. 
TABLE lib - Same as TABLE Ila except that it is doses of methadone, 
clonidine, and naltrexone for subjects 4-8. 
TABLE III - Average daily doses of methadone, clonidine, and naltrexone for 
Group II (subjects 4-8). Methadone is expressed in units of mg/day while 
clonidine and naltrexone are expressed in both units of mg/day and 
yg/kg/day. 
TABLE IV - Average sitting systolic blood pressure, diastolic blood pressure, 
and pulse as well as the average number of withdrawal symptoms vs. day for 
Group II. 
TABLE V - Average frequency of individual withdrawal symptoms vs. day for 
Group II. The frequency was calculated by dividing the number of times a 
symptom was reported in a day by the number of ratings taken during that 
day. More ratings were obtained on various days because the status of the 
subject was changing more rapidly. 
-I 
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TABLE VI - Average clonidine dose per day for ten patients treated with 
clonidine alone as a method of methadone detoxification. The average 
methadone maintenance dose is also indicated for DAY 1. Both methadone 
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